Immunoglobulin molecules having a specific amino acid sequence by virtue of which they interact only with the ANTIGEN (or a very similar shape) that induced their synthesis in cells of the lymphoid series (especially PLASMA CELLS).
Antibodies produced by a single clone of cells.
The property of antibodies which enables them to react with some ANTIGENIC DETERMINANTS and not with others. Specificity is dependent on chemical composition, physical forces, and molecular structure at the binding site.
A measure of the binding strength between antibody and a simple hapten or antigen determinant. It depends on the closeness of stereochemical fit between antibody combining sites and antigen determinants, on the size of the area of contact between them, and on the distribution of charged and hydrophobic groups. It includes the concept of "avidity," which refers to the strength of the antigen-antibody bond after formation of reversible complexes.
Immunoglobulins produced in response to VIRAL ANTIGENS.
Immunoglobulins produced in a response to BACTERIAL ANTIGENS.
Antibodies that reduce or abolish some biological activity of a soluble antigen or infectious agent, usually a virus.
Local surface sites on antibodies which react with antigen determinant sites on antigens (EPITOPES.) They are formed from parts of the variable regions of FAB FRAGMENTS.
The production of ANTIBODIES by proliferating and differentiated B-LYMPHOCYTES under stimulation by ANTIGENS.
Antibodies, often monoclonal, in which the two antigen-binding sites are specific for separate ANTIGENIC DETERMINANTS. They are artificial antibodies produced by chemical crosslinking, fusion of HYBRIDOMA cells, or by molecular genetic techniques. They function as the main mediators of targeted cellular cytotoxicity and have been shown to be efficient in the targeting of drugs, toxins, radiolabeled haptens, and effector cells to diseased tissue, primarily tumors.
Antibodies from non-human species whose protein sequences have been modified to make them nearly identical with human antibodies. If the constant region and part of the variable region are replaced, they are called humanized. If only the constant region is modified they are called chimeric. INN names for humanized antibodies end in -zumab.
Sites on an antigen that interact with specific antibodies.
Immunoglobulins induced by antigens specific for tumors other than the normally occurring HISTOCOMPATIBILITY ANTIGENS.
The phenomenon of antibody-mediated target cell destruction by non-sensitized effector cells. The identity of the target cell varies, but it must possess surface IMMUNOGLOBULIN G whose Fc portion is intact. The effector cell is a "killer" cell possessing Fc receptors. It may be a lymphocyte lacking conventional B- or T-cell markers, or a monocyte, macrophage, or polynuclear leukocyte, depending on the identity of the target cell. The reaction is complement-independent.
A form of antibodies consisting only of the variable regions of the heavy and light chains (FV FRAGMENTS), connected by a small linker peptide. They are less immunogenic than complete immunoglobulin and thus have potential therapeutic use.
The major immunoglobulin isotype class in normal human serum. There are several isotype subclasses of IgG, for example, IgG1, IgG2A, and IgG2B.
Univalent antigen-binding fragments composed of one entire IMMUNOGLOBULIN LIGHT CHAIN and the amino terminal end of one of the IMMUNOGLOBULIN HEAVY CHAINS from the hinge region, linked to each other by disulfide bonds. Fab contains the IMMUNOGLOBULIN VARIABLE REGIONS, which are part of the antigen-binding site, and the first IMMUNOGLOBULIN CONSTANT REGIONS. This fragment can be obtained by digestion of immunoglobulins with the proteolytic enzyme PAPAIN.
Test for tissue antigen using either a direct method, by conjugation of antibody with fluorescent dye (FLUORESCENT ANTIBODY TECHNIQUE, DIRECT) or an indirect method, by formation of antigen-antibody complex which is then labeled with fluorescein-conjugated anti-immunoglobulin antibody (FLUORESCENT ANTIBODY TECHNIQUE, INDIRECT). The tissue is then examined by fluorescence microscopy.
Procedures by which protein structure and function are changed or created in vitro by altering existing or synthesizing new structural genes that direct the synthesis of proteins with sought-after properties. Such procedures may include the design of MOLECULAR MODELS of proteins using COMPUTER GRAPHICS or other molecular modeling techniques; site-specific mutagenesis (MUTAGENESIS, SITE-SPECIFIC) of existing genes; and DIRECTED MOLECULAR EVOLUTION techniques to create new genes.
Antibodies which react with the individual structural determinants (idiotopes) on the variable region of other antibodies.
The use of genetic methodologies to improve functional capacities of an organism rather than to treat disease.
Methods used for studying the interactions of antibodies with specific regions of protein antigens. Important applications of epitope mapping are found within the area of immunochemistry.
Crystallizable fragments composed of the carboxy-terminal halves of both IMMUNOGLOBULIN HEAVY CHAINS linked to each other by disulfide bonds. Fc fragments contain the carboxy-terminal parts of the heavy chain constant regions that are responsible for the effector functions of an immunoglobulin (COMPLEMENT fixation, binding to the cell membrane via FC RECEPTORS, and placental transport). This fragment can be obtained by digestion of immunoglobulins with the proteolytic enzyme PAPAIN.
Serological reactions in which an antiserum against one antigen reacts with a non-identical but closely related antigen.
Unglycosylated phosphoproteins expressed only on B-cells. They are regulators of transmembrane Ca2+ conductance and thought to play a role in B-cell activation and proliferation.
Descriptions of specific amino acid, carbohydrate, or nucleotide sequences which have appeared in the published literature and/or are deposited in and maintained by databanks such as GENBANK, European Molecular Biology Laboratory (EMBL), National Biomedical Research Foundation (NBRF), or other sequence repositories.
Antibodies reactive with HIV ANTIGENS.
Manipulation of the host's immune system in treatment of disease. It includes both active and passive immunization as well as immunosuppressive therapy to prevent graft rejection.
The order of amino acids as they occur in a polypeptide chain. This is referred to as the primary structure of proteins. It is of fundamental importance in determining PROTEIN CONFORMATION.
Immunoglobulins produced in a response to PROTOZOAN ANTIGENS.
Molecules found on the surface of some, but not all, B-lymphocytes, T-lymphocytes, and macrophages, which recognize and combine with the Fc (crystallizable) portion of immunoglobulin molecules.
Partial immunoglobulin molecules resulting from selective cleavage by proteolytic enzymes or generated through PROTEIN ENGINEERING techniques.
Autoantibodies directed against various nuclear antigens including DNA, RNA, histones, acidic nuclear proteins, or complexes of these molecular elements. Antinuclear antibodies are found in systemic autoimmune diseases including systemic lupus erythematosus, Sjogren's syndrome, scleroderma, polymyositis, and mixed connective tissue disease.
A collection of cloned peptides, or chemically synthesized peptides, frequently consisting of all possible combinations of amino acids making up an n-amino acid peptide.
An immunoassay utilizing an antibody labeled with an enzyme marker such as horseradish peroxidase. While either the enzyme or the antibody is bound to an immunosorbent substrate, they both retain their biologic activity; the change in enzyme activity as a result of the enzyme-antibody-antigen reaction is proportional to the concentration of the antigen and can be measured spectrophotometrically or with the naked eye. Many variations of the method have been developed.
Antibodies obtained from a single clone of cells grown in mice or rats.
The measurement of infection-blocking titer of ANTISERA by testing a series of dilutions for a given virus-antiserum interaction end-point, which is generally the dilution at which tissue cultures inoculated with the serum-virus mixtures demonstrate cytopathology (CPE) or the dilution at which 50% of test animals injected with serum-virus mixtures show infectivity (ID50) or die (LD50).
A class of immunoglobulin bearing mu chains (IMMUNOGLOBULIN MU-CHAINS). IgM can fix COMPLEMENT. The name comes from its high molecular weight and originally being called a macroglobulin.
Cells artificially created by fusion of activated lymphocytes with neoplastic cells. The resulting hybrid cells are cloned and produce pure MONOCLONAL ANTIBODIES or T-cell products, identical to those produced by the immunologically competent parent cell.
Specific molecular sites on the surface of various cells, including B-lymphocytes and macrophages, that combine with IMMUNOGLOBULIN Gs. Three subclasses exist: Fc gamma RI (the CD64 antigen, a low affinity receptor), Fc gamma RII (the CD32 antigen, a high affinity receptor), and Fc gamma RIII (the CD16 antigen, a low affinity receptor).
The processes triggered by interactions of ANTIBODIES with their ANTIGENS.
That region of the immunoglobulin molecule that varies in its amino acid sequence and composition, and comprises the binding site for a specific antigen. It is located at the N-terminus of the Fab fragment of the immunoglobulin. It includes hypervariable regions (COMPLEMENTARITY DETERMINING REGIONS) and framework regions.
Antibodies that react with self-antigens (AUTOANTIGENS) of the organism that produced them.
Body of knowledge related to the use of organisms, cells or cell-derived constituents for the purpose of developing products which are technically, scientifically and clinically useful. Alteration of biologic function at the molecular level (i.e., GENETIC ENGINEERING) is a central focus; laboratory methods used include TRANSFECTION and CLONING technologies, sequence and structure analysis algorithms, computer databases, and gene and protein structure function analysis and prediction.
Proteins prepared by recombinant DNA technology.
A biosensing technique in which biomolecules capable of binding to specific analytes or ligands are first immobilized on one side of a metallic film. Light is then focused on the opposite side of the film to excite the surface plasmons, that is, the oscillations of free electrons propagating along the film's surface. The refractive index of light reflecting off this surface is measured. When the immobilized biomolecules are bound by their ligands, an alteration in surface plasmons on the opposite side of the film is created which is directly proportional to the change in bound, or adsorbed, mass. Binding is measured by changes in the refractive index. The technique is used to study biomolecular interactions, such as antigen-antibody binding.
The molecular designing of drugs for specific purposes (such as DNA-binding, enzyme inhibition, anti-cancer efficacy, etc.) based on knowledge of molecular properties such as activity of functional groups, molecular geometry, and electronic structure, and also on information cataloged on analogous molecules. Drug design is generally computer-assisted molecular modeling and does not include pharmacokinetics, dosage analysis, or drug administration analysis.
Immunoglobulins produced in a response to FUNGAL ANTIGENS.
A genus of the family Muridae consisting of eleven species. C. migratorius, the grey or Armenian hamster, and C. griseus, the Chinese hamster, are the two species used in biomedical research.
Established cell cultures that have the potential to propagate indefinitely.
CELL LINE derived from the ovary of the Chinese hamster, Cricetulus griseus (CRICETULUS). The species is a favorite for cytogenetic studies because of its small chromosome number. The cell line has provided model systems for the study of genetic alterations in cultured mammalian cells.
The process in which substances, either endogenous or exogenous, bind to proteins, peptides, enzymes, protein precursors, or allied compounds. Specific protein-binding measures are often used as assays in diagnostic assessments.
A cell line derived from cultured tumor cells.
Antigens on surfaces of cells, including infectious or foreign cells or viruses. They are usually protein-containing groups on cell membranes or walls and may be isolated.
Antibodies that inhibit the reaction between ANTIGEN and other antibodies or sensitized T-LYMPHOCYTES (e.g., antibodies of the IMMUNOGLOBULIN G class that compete with IGE antibodies for antigen, thereby blocking an allergic response). Blocking antibodies that bind tumors and prevent destruction of tumor cells by CYTOTOXIC T-LYMPHOCYTES have also been called enhancing antibodies. (Rosen et al., Dictionary of Immunology, 1989)
Immunologic techniques based on the use of: (1) enzyme-antibody conjugates; (2) enzyme-antigen conjugates; (3) antienzyme antibody followed by its homologous enzyme; or (4) enzyme-antienzyme complexes. These are used histologically for visualizing or labeling tissue specimens.
Technique using an instrument system for making, processing, and displaying one or more measurements on individual cells obtained from a cell suspension. Cells are usually stained with one or more fluorescent dyes specific to cell components of interest, e.g., DNA, and fluorescence of each cell is measured as it rapidly transverses the excitation beam (laser or mercury arc lamp). Fluorescence provides a quantitative measure of various biochemical and biophysical properties of the cell, as well as a basis for cell sorting. Other measurable optical parameters include light absorption and light scattering, the latter being applicable to the measurement of cell size, shape, density, granularity, and stain uptake.
The species Oryctolagus cuniculus, in the family Leporidae, order LAGOMORPHA. Rabbits are born in burrows, furless, and with eyes and ears closed. In contrast with HARES, rabbits have 22 chromosome pairs.
New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.
Antibodies elicited in a different species from which the antigen originated. These antibodies are directed against a wide variety of interspecies-specific antigens, the best known of which are Forssman, Hanganutziu-Deicher (H-D), and Paul-Bunnell (P-B). Incidence of antibodies to these antigens--i.e., the phenomenon of heterophile antibody response--is useful in the serodiagnosis, pathogenesis, and prognosis of infection and latent infectious states as well as in cancer classification.
Recombinant proteins produced by the GENETIC TRANSLATION of fused genes formed by the combination of NUCLEIC ACID REGULATORY SEQUENCES of one or more genes with the protein coding sequences of one or more genes.
The complex formed by the binding of antigen and antibody molecules. The deposition of large antigen-antibody complexes leading to tissue damage causes IMMUNE COMPLEX DISEASES.
A species of the genus MACACA which typically lives near the coast in tidal creeks and mangrove swamps primarily on the islands of the Malay peninsula.
Antibodies that can catalyze a wide variety of chemical reactions. They are characterized by high substrate specificity and share many mechanistic features with enzymes.
A form of fluorescent antibody technique commonly used to detect serum antibodies and immune complexes in tissues and microorganisms in specimens from patients with infectious diseases. The technique involves formation of an antigen-antibody complex which is labeled with fluorescein-conjugated anti-immunoglobulin antibody. (From Bennington, Saunders Dictionary & Encyclopedia of Laboratory Medicine and Technology, 1984)
Models used experimentally or theoretically to study molecular shape, electronic properties, or interactions; includes analogous molecules, computer-generated graphics, and mechanical structures.
Represents 15-20% of the human serum immunoglobulins, mostly as the 4-chain polymer in humans or dimer in other mammals. Secretory IgA (IMMUNOGLOBULIN A, SECRETORY) is the main immunoglobulin in secretions.
The sum of the weight of all the atoms in a molecule.
A subfamily in the family MURIDAE, comprising the hamsters. Four of the more common genera are Cricetus, CRICETULUS; MESOCRICETUS; and PHODOPUS.
Serum that contains antibodies. It is obtained from an animal that has been immunized either by ANTIGEN injection or infection with microorganisms containing the antigen.
A cell surface protein-tyrosine kinase receptor that is overexpressed in a variety of ADENOCARCINOMAS. It has extensive homology to and heterodimerizes with the EGF RECEPTOR, the ERBB-3 RECEPTOR, and the ERBB-4 RECEPTOR. Activation of the erbB-2 receptor occurs through heterodimer formation with a ligand-bound erbB receptor family member.
Substances that are recognized by the immune system and induce an immune reaction.
Substances elaborated by bacteria that have antigenic activity.
Transfer of immunity from immunized to non-immune host by administration of serum antibodies, or transplantation of lymphocytes (ADOPTIVE TRANSFER).
Histochemical localization of immunoreactive substances using labeled antibodies as reagents.
Substances that inhibit or prevent the proliferation of NEOPLASMS.
Proteins, glycoprotein, or lipoprotein moieties on surfaces of tumor cells that are usually identified by monoclonal antibodies. Many of these are of either embryonic or viral origin.
Deliberate stimulation of the host's immune response. ACTIVE IMMUNIZATION involves administration of ANTIGENS or IMMUNOLOGIC ADJUVANTS. PASSIVE IMMUNIZATION involves administration of IMMUNE SERA or LYMPHOCYTES or their extracts (e.g., transfer factor, immune RNA) or transplantation of immunocompetent cell producing tissue (thymus or bone marrow).
Mice homozygous for the mutant autosomal recessive gene "scid" which is located on the centromeric end of chromosome 16. These mice lack mature, functional lymphocytes and are thus highly susceptible to lethal opportunistic infections if not chronically treated with antibiotics. The lack of B- and T-cell immunity resembles severe combined immunodeficiency (SCID) syndrome in human infants. SCID mice are useful as animal models since they are receptive to implantation of a human immune system producing SCID-human (SCID-hu) hematochimeric mice.
Identification of proteins or peptides that have been electrophoretically separated by blot transferring from the electrophoresis gel to strips of nitrocellulose paper, followed by labeling with antibody probes.
Electrophoresis in which a polyacrylamide gel is used as the diffusion medium.
Substances elaborated by viruses that have antigenic activity.
A technique using antibodies for identifying or quantifying a substance. Usually the substance being studied serves as antigen both in antibody production and in measurement of antibody by the test substance.
The process of finding chemicals for potential therapeutic use.
Classic quantitative assay for detection of antigen-antibody reactions using a radioactively labeled substance (radioligand) either directly or indirectly to measure the binding of the unlabeled substance to a specific antibody or other receptor system. Non-immunogenic substances (e.g., haptens) can be measured if coupled to larger carrier proteins (e.g., bovine gamma-globulin or human serum albumin) capable of inducing antibody formation.
Autoantibodies directed against phospholipids. These antibodies are characteristically found in patients with systemic lupus erythematosus (LUPUS ERYTHEMATOSUS, SYSTEMIC;), ANTIPHOSPHOLIPID SYNDROME; related autoimmune diseases, some non-autoimmune diseases, and also in healthy individuals.
Immunologic method used for detecting or quantifying immunoreactive substances. The substance is identified by first immobilizing it by blotting onto a membrane and then tagging it with labeled antibodies.
Lymphoid cells concerned with humoral immunity. They are short-lived cells resembling bursa-derived lymphocytes of birds in their production of immunoglobulin upon appropriate stimulation.
Unique genetically-controlled determinants present on ANTIBODIES whose specificity is limited to a single group of proteins (e.g., another antibody molecule or an individual myeloma protein). The idiotype appears to represent the antigenicity of the antigen-binding site of the antibody and to be genetically codetermined with it. The idiotypic determinants have been precisely located to the IMMUNOGLOBULIN VARIABLE REGION of both immunoglobin polypeptide chains.
Cells propagated in vitro in special media conducive to their growth. Cultured cells are used to study developmental, morphologic, metabolic, physiologic, and genetic processes, among others.
In vivo methods of screening investigative anticancer drugs, biologic response modifiers or radiotherapies. Human tumor tissue or cells are transplanted into mice or rats followed by tumor treatment regimens. A variety of outcomes are monitored to assess antitumor effectiveness.
The level of protein structure in which combinations of secondary protein structures (alpha helices, beta sheets, loop regions, and motifs) pack together to form folded shapes called domains. Disulfide bridges between cysteines in two different parts of the polypeptide chain along with other interactions between the chains play a role in the formation and stabilization of tertiary structure. Small proteins usually consist of only one domain but larger proteins may contain a number of domains connected by segments of polypeptide chain which lack regular secondary structure.
Techniques for removal by adsorption and subsequent elution of a specific antibody or antigen using an immunosorbent containing the homologous antigen or antibody.
Lymphocytes responsible for cell-mediated immunity. Two types have been identified - cytotoxic (T-LYMPHOCYTES, CYTOTOXIC) and helper T-lymphocytes (T-LYMPHOCYTES, HELPER-INDUCER). They are formed when lymphocytes circulate through the THYMUS GLAND and differentiate to thymocytes. When exposed to an antigen, they divide rapidly and produce large numbers of new T cells sensitized to that antigen.
Techniques used to demonstrate or measure an immune response, and to identify or measure antigens using antibodies.
The sequence of PURINES and PYRIMIDINES in nucleic acids and polynucleotides. It is also called nucleotide sequence.
Conjugated protein-carbohydrate compounds including mucins, mucoid, and amyloid glycoproteins.
Bone marrow-derived lymphocytes that possess cytotoxic properties, classically directed against transformed and virus-infected cells. Unlike T CELLS; and B CELLS; NK CELLS are not antigen specific. The cytotoxicity of natural killer cells is determined by the collective signaling of an array of inhibitory and stimulatory CELL SURFACE RECEPTORS. A subset of T-LYMPHOCYTES referred to as NATURAL KILLER T CELLS shares some of the properties of this cell type.
A cell surface receptor involved in regulation of cell growth and differentiation. It is specific for EPIDERMAL GROWTH FACTOR and EGF-related peptides including TRANSFORMING GROWTH FACTOR ALPHA; AMPHIREGULIN; and HEPARIN-BINDING EGF-LIKE GROWTH FACTOR. The binding of ligand to the receptor causes activation of its intrinsic tyrosine kinase activity and rapid internalization of the receptor-ligand complex into the cell.
The interaction of two or more substrates or ligands with the same binding site. The displacement of one by the other is used in quantitative and selective affinity measurements.
The chemical or biochemical addition of carbohydrate or glycosyl groups to other chemicals, especially peptides or proteins. Glycosyl transferases are used in this biochemical reaction.
Membrane glycoproteins consisting of an alpha subunit and a BETA 2-MICROGLOBULIN beta subunit. In humans, highly polymorphic genes on CHROMOSOME 6 encode the alpha subunits of class I antigens and play an important role in determining the serological specificity of the surface antigen. Class I antigens are found on most nucleated cells and are generally detected by their reactivity with alloantisera. These antigens are recognized during GRAFT REJECTION and restrict cell-mediated lysis of virus-infected cells.
The study of crystal structure using X-RAY DIFFRACTION techniques. (McGraw-Hill Dictionary of Scientific and Technical Terms, 4th ed)
Domesticated bovine animals of the genus Bos, usually kept on a farm or ranch and used for the production of meat or dairy products or for heavy labor.
Serologic tests in which a known quantity of antigen is added to the serum prior to the addition of a red cell suspension. Reaction result is expressed as the smallest amount of antigen which causes complete inhibition of hemagglutination.
Sensitive tests to measure certain antigens, antibodies, or viruses, using their ability to agglutinate certain erythrocytes. (From Stedman, 26th ed)
Partial proteins formed by partial hydrolysis of complete proteins or generated through PROTEIN ENGINEERING techniques.
Multi-subunit proteins which function in IMMUNITY. They are produced by B LYMPHOCYTES from the IMMUNOGLOBULIN GENES. They are comprised of two heavy (IMMUNOGLOBULIN HEAVY CHAINS) and two light chains (IMMUNOGLOBULIN LIGHT CHAINS) with additional ancillary polypeptide chains depending on their isoforms. The variety of isoforms include monomeric or polymeric forms, and transmembrane forms (B-CELL ANTIGEN RECEPTORS) or secreted forms (ANTIBODIES). They are divided by the amino acid sequence of their heavy chains into five classes (IMMUNOGLOBULIN A; IMMUNOGLOBULIN D; IMMUNOGLOBULIN E; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M) and various subclasses.
The classes of immunoglobulins found in any species of animal. In man there are nine classes that migrate in five different groups in electrophoresis; they each consist of two light and two heavy protein chains, and each group has distinguishing structural and functional properties.
The restriction of a characteristic behavior, anatomical structure or physical system, such as immune response; metabolic response, or gene or gene variant to the members of one species. It refers to that property which differentiates one species from another but it is also used for phylogenetic levels higher or lower than the species.
Unstable isotopes of iodine that decay or disintegrate emitting radiation. I atoms with atomic weights 117-139, except I 127, are radioactive iodine isotopes.
Serologic tests based on inactivation of complement by the antigen-antibody complex (stage 1). Binding of free complement can be visualized by addition of a second antigen-antibody system such as red cells and appropriate red cell antibody (hemolysin) requiring complement for its completion (stage 2). Failure of the red cells to lyse indicates that a specific antigen-antibody reaction has taken place in stage 1. If red cells lyse, free complement is present indicating no antigen-antibody reaction occurred in stage 1.
Differentiation antigens residing on mammalian leukocytes. CD stands for cluster of differentiation, which refers to groups of monoclonal antibodies that show similar reactivity with certain subpopulations of antigens of a particular lineage or differentiation stage. The subpopulations of antigens are also known by the same CD designation.
Small antigenic determinants capable of eliciting an immune response only when coupled to a carrier. Haptens bind to antibodies but by themselves cannot elicit an antibody response.
Accumulation of a drug or chemical substance in various organs (including those not relevant to its pharmacologic or therapeutic action). This distribution depends on the blood flow or perfusion rate of the organ, the ability of the drug to penetrate organ membranes, tissue specificity, protein binding. The distribution is usually expressed as tissue to plasma ratios.
Antibodies from an individual that react with ISOANTIGENS of another individual of the same species.
A chromatographic technique that utilizes the ability of biological molecules to bind to certain ligands specifically and reversibly. It is used in protein biochemistry. (McGraw-Hill Dictionary of Scientific and Technical Terms, 4th ed)
Elements of limited time intervals, contributing to particular results or situations.
Binary classification measures to assess test results. Sensitivity or recall rate is the proportion of true positives. Specificity is the probability of correctly determining the absence of a condition. (From Last, Dictionary of Epidemiology, 2d ed)
Serologic tests in which a positive reaction manifested by visible CHEMICAL PRECIPITATION occurs when a soluble ANTIGEN reacts with its precipitins, i.e., ANTIBODIES that can form a precipitate.
Autoantibodies directed against cytoplasmic constituents of POLYMORPHONUCLEAR LEUKOCYTES and/or MONOCYTES. They are used as specific markers for GRANULOMATOSIS WITH POLYANGIITIS and other diseases, though their pathophysiological role is not clear. ANCA are routinely detected by indirect immunofluorescence with three different patterns: c-ANCA (cytoplasmic), p-ANCA (perinuclear), and atypical ANCA.
Serum glycoproteins participating in the host defense mechanism of COMPLEMENT ACTIVATION that creates the COMPLEMENT MEMBRANE ATTACK COMPLEX. Included are glycoproteins in the various pathways of complement activation (CLASSICAL COMPLEMENT PATHWAY; ALTERNATIVE COMPLEMENT PATHWAY; and LECTIN COMPLEMENT PATHWAY).
Cells grown in vitro from neoplastic tissue. If they can be established as a TUMOR CELL LINE, they can be propagated in cell culture indefinitely.
Radiotherapy where cytotoxic radionuclides are linked to antibodies in order to deliver toxins directly to tumor targets. Therapy with targeted radiation rather than antibody-targeted toxins (IMMUNOTOXINS) has the advantage that adjacent tumor cells, which lack the appropriate antigenic determinants, can be destroyed by radiation cross-fire. Radioimmunotherapy is sometimes called targeted radiotherapy, but this latter term can also refer to radionuclides linked to non-immune molecules (see RADIOTHERAPY).
Polypeptide chains, consisting of 211 to 217 amino acid residues and having a molecular weight of approximately 22 kDa. There are two major types of light chains, kappa and lambda. Two Ig light chains and two Ig heavy chains (IMMUNOGLOBULIN HEAVY CHAINS) make one immunoglobulin molecule.
The phenomenon of immense variability characteristic of ANTIBODIES. It enables the IMMUNE SYSTEM to react specifically against the essentially unlimited kinds of ANTIGENS it encounters. Antibody diversity is accounted for by three main theories: (1) the Germ Line Theory, which holds that each antibody-producing cell has genes coding for all possible antibody specificities, but expresses only the one stimulated by antigen; (2) the Somatic Mutation Theory, which holds that antibody-producing cells contain only a few genes, which produce antibody diversity by mutation; and (3) the Gene Rearrangement Theory, which holds that antibody diversity is generated by the rearrangement of IMMUNOGLOBULIN VARIABLE REGION gene segments during the differentiation of the ANTIBODY-PRODUCING CELLS.
EPIDEMIOLOGIC STUDIES based on the detection through serological testing of characteristic change in the serum level of specific ANTIBODIES. Latent subclinical infections and carrier states can thus be detected in addition to clinically overt cases.
An encapsulated lymphatic organ through which venous blood filters.
The rate dynamics in chemical or physical systems.
Glycoproteins found on the membrane or surface of cells.
The largest of polypeptide chains comprising immunoglobulins. They contain 450 to 600 amino acid residues per chain, and have molecular weights of 51-72 kDa.
Members of the class of compounds composed of AMINO ACIDS joined together by peptide bonds between adjacent amino acids into linear, branched or cyclical structures. OLIGOPEPTIDES are composed of approximately 2-12 amino acids. Polypeptides are composed of approximately 13 or more amino acids. PROTEINS are linear polypeptides that are normally synthesized on RIBOSOMES.
Field of chemistry that pertains to immunological phenomena and the study of chemical reactions related to antigen stimulation of tissues. It includes physicochemical interactions between antigens and antibodies.
Layers of protein which surround the capsid in animal viruses with tubular nucleocapsids. The envelope consists of an inner layer of lipids and virus specified proteins also called membrane or matrix proteins. The outer layer consists of one or more types of morphological subunits called peplomers which project from the viral envelope; this layer always consists of glycoproteins.
Use of radiolabeled antibodies for diagnostic imaging of neoplasms. Antitumor antibodies are labeled with diverse radionuclides including iodine-131, iodine-123, indium-111, or technetium-99m and injected into the patient. Images are obtained by a scintillation camera.
Semisynthetic conjugates of various toxic molecules, including RADIOACTIVE ISOTOPES and bacterial or plant toxins, with specific immune substances such as IMMUNOGLOBULINS; MONOCLONAL ANTIBODIES; and ANTIGENS. The antitumor or antiviral immune substance carries the toxin to the tumor or infected cell where the toxin exerts its poisonous effect.
The insertion of recombinant DNA molecules from prokaryotic and/or eukaryotic sources into a replicating vehicle, such as a plasmid or virus vector, and the introduction of the resultant hybrid molecules into recipient cells without altering the viability of those cells.
Technique involving the diffusion of antigen or antibody through a semisolid medium, usually agar or agarose gel, with the result being a precipitin reaction.
Genetically identical individuals developed from brother and sister matings which have been carried out for twenty or more generations, or by parent x offspring matings carried out with certain restrictions. All animals within an inbred strain trace back to a common ancestor in the twentieth generation.
Antibodies to the HEPATITIS C ANTIGENS including antibodies to envelope, core, and non-structural proteins.
Morphologic alteration of small B LYMPHOCYTES or T LYMPHOCYTES in culture into large blast-like cells able to synthesize DNA and RNA and to divide mitotically. It is induced by INTERLEUKINS; MITOGENS such as PHYTOHEMAGGLUTININS, and by specific ANTIGENS. It may also occur in vivo as in GRAFT REJECTION.
Endogenous tissue constituents that have the ability to interact with AUTOANTIBODIES and cause an immune response.
Administration of vaccines to stimulate the host's immune response. This includes any preparation intended for active immunological prophylaxis.
White blood cells formed in the body's lymphoid tissue. The nucleus is round or ovoid with coarse, irregularly clumped chromatin while the cytoplasm is typically pale blue with azurophilic (if any) granules. Most lymphocytes can be classified as either T or B (with subpopulations of each), or NATURAL KILLER CELLS.
Proteins which are found in membranes including cellular and intracellular membranes. They consist of two types, peripheral and integral proteins. They include most membrane-associated enzymes, antigenic proteins, transport proteins, and drug, hormone, and lectin receptors.
A chronic, relapsing, inflammatory, and often febrile multisystemic disorder of connective tissue, characterized principally by involvement of the skin, joints, kidneys, and serosal membranes. It is of unknown etiology, but is thought to represent a failure of the regulatory mechanisms of the autoimmune system. The disease is marked by a wide range of system dysfunctions, an elevated erythrocyte sedimentation rate, and the formation of LE cells in the blood or bone marrow.
A specific immune response elicited by a specific dose of an immunologically active substance or cell in an organism, tissue, or cell.
Antibodies to the HEPATITIS B ANTIGENS, including antibodies to the surface (Australia) and core of the Dane particle and those to the "e" antigens.
Microscopy using an electron beam, instead of light, to visualize the sample, thereby allowing much greater magnification. The interactions of ELECTRONS with specimens are used to provide information about the fine structure of that specimen. In TRANSMISSION ELECTRON MICROSCOPY the reactions of the electrons that are transmitted through the specimen are imaged. In SCANNING ELECTRON MICROSCOPY an electron beam falls at a non-normal angle on the specimen and the image is derived from the reactions occurring above the plane of the specimen.
Polysaccharides found in bacteria and in capsules thereof.
Microscopy in which the samples are first stained immunocytochemically and then examined using an electron microscope. Immunoelectron microscopy is used extensively in diagnostic virology as part of very sensitive immunoassays.
Resistance to a disease-causing agent induced by the introduction of maternal immunity into the fetus by transplacental transfer or into the neonate through colostrum and milk.
The lipid- and protein-containing, selectively permeable membrane that surrounds the cytoplasm in prokaryotic and eukaryotic cells.
Conditions characterized by the presence of M protein (Monoclonal protein) in serum or urine without clinical manifestations of plasma cell dyscrasia.
Antibodies specific to INSULIN.
Disorders that are characterized by the production of antibodies that react with host tissues or immune effector cells that are autoreactive to endogenous peptides.
Red blood cells. Mature erythrocytes are non-nucleated, biconcave disks containing HEMOGLOBIN whose function is to transport OXYGEN.
Diagnostic procedures involving immunoglobulin reactions.
Adherence of cells to surfaces or to other cells.
Antigenic determinants recognized and bound by the B-cell receptor. Epitopes recognized by the B-cell receptor are located on the surface of the antigen.
A group of related diseases characterized by an unbalanced or disproportionate proliferation of immunoglobulin-producing cells, usually from a single clone. These cells frequently secrete a structurally homogeneous immunoglobulin (M-component) and/or an abnormal immunoglobulin.
A technique that combines protein electrophoresis and double immunodiffusion. In this procedure proteins are first separated by gel electrophoresis (usually agarose), then made visible by immunodiffusion of specific antibodies. A distinct elliptical precipitin arc results for each protein detectable by the antisera.
Unstable isotopes of indium that decay or disintegrate emitting radiation. In atoms with atomic weights 106-112, 113m, 114, and 116-124 are radioactive indium isotopes.
The characteristic 3-dimensional shape of a protein, including the secondary, supersecondary (motifs), tertiary (domains) and quaternary structure of the peptide chain. PROTEIN STRUCTURE, QUATERNARY describes the conformation assumed by multimeric proteins (aggregates of more than one polypeptide chain).
An immunoglobulin fragment composed of one variable domain from an IMMUNOGLOBULIN HEAVY CHAIN or IMMUNOGLOBULIN LIGHT CHAIN.
Suspensions of attenuated or killed bacteria administered for the prevention or treatment of infectious bacterial disease.
Any part or derivative of any protozoan that elicits immunity; malaria (Plasmodium) and trypanosome antigens are presently the most frequently encountered.
Mutant mice homozygous for the recessive gene "nude" which fail to develop a thymus. They are useful in tumor studies and studies on immune responses.
Tests that are dependent on the clumping of cells, microorganisms, or particles when mixed with specific antiserum. (From Stedman, 26th ed)
Any of various animals that constitute the family Suidae and comprise stout-bodied, short-legged omnivorous mammals with thick skin, usually covered with coarse bristles, a rather long mobile snout, and small tail. Included are the genera Babyrousa, Phacochoerus (wart hogs), and Sus, the latter containing the domestic pig (see SUS SCROFA).
RNA sequences that serve as templates for protein synthesis. Bacterial mRNAs are generally primary transcripts in that they do not require post-transcriptional processing. Eukaryotic mRNA is synthesized in the nucleus and must be exported to the cytoplasm for translation. Most eukaryotic mRNAs have a sequence of polyadenylic acid at the 3' end, referred to as the poly(A) tail. The function of this tail is not known for certain, but it may play a role in the export of mature mRNA from the nucleus as well as in helping stabilize some mRNA molecules by retarding their degradation in the cytoplasm.
An immunoglobulin associated with MAST CELLS. Overexpression has been associated with allergic hypersensitivity (HYPERSENSITIVITY, IMMEDIATE).
A species of gram-negative, facultatively anaerobic, rod-shaped bacteria (GRAM-NEGATIVE FACULTATIVELY ANAEROBIC RODS) commonly found in the lower part of the intestine of warm-blooded animals. It is usually nonpathogenic, but some strains are known to produce DIARRHEA and pyogenic infections. Pathogenic strains (virotypes) are classified by their specific pathogenic mechanisms such as toxins (ENTEROTOXIGENIC ESCHERICHIA COLI), etc.
Common name for the species Gallus gallus, the domestic fowl, in the family Phasianidae, order GALLIFORMES. It is descended from the red jungle fowl of SOUTHEAST ASIA.
External envelope protein of the human immunodeficiency virus which is encoded by the HIV env gene. It has a molecular weight of 120 kDa and contains numerous glycosylation sites. Gp120 binds to cells expressing CD4 cell-surface antigens, most notably T4-lymphocytes and monocytes/macrophages. Gp120 has been shown to interfere with the normal function of CD4 and is at least partly responsible for the cytopathic effect of HIV.
The type species of LENTIVIRUS and the etiologic agent of AIDS. It is characterized by its cytopathic effect and affinity for the T4-lymphocyte.
The parts of a macromolecule that directly participate in its specific combination with another molecule.
Naturally occurring or experimentally induced animal diseases with pathological processes sufficiently similar to those of human diseases. They are used as study models for human diseases.
Proteins found in any species of virus.
A subclass of ACIDIC GLYCOSPHINGOLIPIDS. They contain one or more sialic acid (N-ACETYLNEURAMINIC ACID) residues. Using the Svennerholm system of abbrevations, gangliosides are designated G for ganglioside, plus subscript M, D, or T for mono-, di-, or trisialo, respectively, the subscript letter being followed by a subscript arabic numeral to indicated sequence of migration in thin-layer chromatograms. (From Oxford Dictionary of Biochemistry and Molecular Biology, 1997)
A deoxyribonucleotide polymer that is the primary genetic material of all cells. Eukaryotic and prokaryotic organisms normally contain DNA in a double-stranded state, yet several important biological processes transiently involve single-stranded regions. DNA, which consists of a polysugar-phosphate backbone possessing projections of purines (adenine and guanine) and pyrimidines (thymine and cytosine), forms a double helix that is held together by hydrogen bonds between these purines and pyrimidines (adenine to thymine and guanine to cytosine).
The fission of a CELL. It includes CYTOKINESIS, when the CYTOPLASM of a cell is divided, and CELL NUCLEUS DIVISION.
A group of genetically identical cells all descended from a single common ancestral cell by mitosis in eukaryotes or by binary fission in prokaryotes. Clone cells also include populations of recombinant DNA molecules all carrying the same inserted sequence. (From King & Stansfield, Dictionary of Genetics, 4th ed)
Suspensions of attenuated or killed viruses administered for the prevention or treatment of infectious viral disease.
In vitro method for producing large amounts of specific DNA or RNA fragments of defined length and sequence from small amounts of short oligonucleotide flanking sequences (primers). The essential steps include thermal denaturation of the double-stranded target molecules, annealing of the primers to their complementary sequences, and extension of the annealed primers by enzymatic synthesis with DNA polymerase. The reaction is efficient, specific, and extremely sensitive. Uses for the reaction include disease diagnosis, detection of difficult-to-isolate pathogens, mutation analysis, genetic testing, DNA sequencing, and analyzing evolutionary relationships.
Proteins isolated from the outer membrane of Gram-negative bacteria.
A glycoprotein that is secreted into the luminal surface of the epithelia in the gastrointestinal tract. It is found in the feces and pancreaticobiliary secretions and is used to monitor the response to colon cancer treatment.
The phenomenon of target cell destruction by immunologically active effector cells. It may be brought about directly by sensitized T-lymphocytes or by lymphoid or myeloid "killer" cells, or it may be mediated by cytotoxic antibody, cytotoxic factor released by lymphoid cells, or complement.
A form of fluorescent antibody technique utilizing a fluorochrome conjugated to an antibody, which is added directly to a tissue or cell suspension for the detection of a specific antigen. (Bennington, Saunders Dictionary & Encyclopedia of Laboratory Medicine and Technology, 1984)
The marking of biological material with a dye or other reagent for the purpose of identifying and quantitating components of tissues, cells or their extracts.
Cell surface proteins that bind signalling molecules external to the cell with high affinity and convert this extracellular event into one or more intracellular signals that alter the behavior of the target cell (From Alberts, Molecular Biology of the Cell, 2nd ed, pp693-5). Cell surface receptors, unlike enzymes, do not chemically alter their ligands.
Proteins found in any species of bacterium.
Surface ligands, usually glycoproteins, that mediate cell-to-cell adhesion. Their functions include the assembly and interconnection of various vertebrate systems, as well as maintenance of tissue integration, wound healing, morphogenic movements, cellular migrations, and metastasis.
Process of determining and distinguishing species of bacteria or viruses based on antigens they share.
Experimental transplantation of neoplasms in laboratory animals for research purposes.
Small synthetic peptides that mimic surface antigens of pathogens and are immunogenic, or vaccines manufactured with the aid of recombinant DNA techniques. The latter vaccines may also be whole viruses whose nucleic acids have been modified.
Lipid-containing polysaccharides which are endotoxins and important group-specific antigens. They are often derived from the cell wall of gram-negative bacteria and induce immunoglobulin secretion. The lipopolysaccharide molecule consists of three parts: LIPID A, core polysaccharide, and O-specific chains (O ANTIGENS). When derived from Escherichia coli, lipopolysaccharides serve as polyclonal B-cell mitogens commonly used in laboratory immunology. (From Dorland, 28th ed)
Antibodies found in adult RHEUMATOID ARTHRITIS patients that are directed against GAMMA-CHAIN IMMUNOGLOBULINS.
The relatively long-lived phagocytic cell of mammalian tissues that are derived from blood MONOCYTES. Main types are PERITONEAL MACROPHAGES; ALVEOLAR MACROPHAGES; HISTIOCYTES; KUPFFER CELLS of the liver; and OSTEOCLASTS. They may further differentiate within chronic inflammatory lesions to EPITHELIOID CELLS or may fuse to form FOREIGN BODY GIANT CELLS or LANGHANS GIANT CELLS. (from The Dictionary of Cell Biology, Lackie and Dow, 3rd ed.)
Monoclonal antibodies (Various). *Additional products (tumour necrosis factor, therapeutic enzymes). Research and development ... humanized monoclonal antibody HER2/neu (erbB2) antagonist ustekinumab Stelara psoriasis humanized monoclonal antibody IL-12 and ... Monoclonal antibodies. These are similar to the antibodies that the human immune system uses to fight off bacteria and viruses ... monoclonal antibody TNF antagonist alefacept Amevive chronic plaque psoriasis immunoglobin G1 fusion protein incompletely ...
Alder specializes in therapeutic monoclonal antibodies. In May 2014, Alder went public. In early 2018, the company made a ... The company identifies, develops, and manufactures antibody therapeutics to alleviate human suffering in cancer, pain, ...
... a new therapeutic monoclonal antibody for non-Hodgkin's lymphoma". Cancer Pract. 6 (3): 195-7. doi:10.1046/j.1523-5394.1998. ... Other anti-CD20 monoclonals[edit]. The efficacy and success of Rituximab has led to some other anti-CD20 monoclonal antibodies ... antibody-dependent cellular cytotoxicity).[55] This strategy for enhancing a monoclonal antibody's ability to induce ADCC takes ... Rituximab is a chimeric monoclonal antibody against the protein CD20, which is primarily found on the surface of immune system ...
Zhiqiang An (8 September 2009). Therapeutic Monoclonal Antibodies: From Bench to Clinic. John Wiley and Sons. pp. 134-. ISBN ... Ipilimumab, sold under the brand name Yervoy, is a monoclonal antibody medication that works to activate the immune system by ... By 2007, there were two fully human anti CTLA-4 monoclonal antibodies in advanced clinical trials. Ipilimumab, which is an IgG1 ... The concept of using anti-CTLA4 antibodies to treat cancer was first developed by James P. Allison while he was director of the ...
Tsurushita N, Vasquez M (January 2004). "Humanization of monoclonal antibodies". In Reth M, Radbruch A, Alt F, Honjo T, ... ISBN 978-0-08-047950-7. "Anti-MS4A1 Therapeutic Antibody (Technetium (99MTC) Nofetumomab Merpentan)". Creative BioLabs. Mudd E ... Technetium (99mTc) nofetumomab merpentan (trade name Verluma) is a mouse monoclonal antibody derivative used in the diagnosis ... 27 February 2015). "Monoclonal Antibody Radionuclide Test Kits". Pharmacological Sciences. US 3934010, Drabek J, Varsanyi D, " ...
"Monoclonal Antibodies Approved by the EMA and FDA for Therapeutic Use - ACTIP". Retrieved 2018-10-24. Rawla P, ... The monoclonal antibody infliximab is a mouse-human chimeric antibody to TNF-α. The FDA approved it in 1998, making it the ... Anti-drug antibodies can cause negative side effects, accelerate the rate of drug clearance, and reduce the therapeutic effects ... In 1988, a monoclonal antibody called infliximab was discovered at New York University's School of Medicine. Infliximab works ...
Many therapeutic approaches are aimed at the EGFR. Cetuximab and panitumumab are examples of monoclonal antibody inhibitors. ... Other monoclonals in clinical development are zalutumumab, nimotuzumab, and matuzumab. The monoclonal antibodies block the ... EGFR is a well-established target for monoclonal antibodies and specific tyrosine kinase inhibitors. Imaging agents have been ... Yan L, Beckman RA (October 2005). "Pharmacogenetics and pharmacogenomics in oncology therapeutic antibody development". ...
Fabs are a common form-factor for monoclonal antibodies designated for therapeutic use. The Fab abciximab, which inhibits blood ... Fab antibodies also have diagnostic use. Arcitumomab is a mouse antibody that recognizes Carcinoembryonic antigen, an antigen ... An antibody digested by papain yields three fragments: two Fab fragments and one Fc fragment An antibody digested by pepsin ... The antigen-binding fragment (Fab) is a region on an antibody that binds to antigens. It is composed of one constant and one ...
"Immunotherapy of a viral disease by in vivo production of therapeutic monoclonal antibodies". Human Gene Therapy. 11 (10): 1407 ... successfully encapsulated antibody producing hybridoma cells and demonstrated subsequent release of the therapeutic antibody ... The use of monoclonal antibodies for therapy is now widespread for treatment of cancers and inflammatory diseases. Using ... "Systemic long-term delivery of antibodies in immunocompetent animals using cellulose sulphate capsules containing antibody- ...
"Monoclonal antibody-based filovirus therapeutic licensed to Leaf Biopharmaceutical" (PDF). 15 July 2014. Davidson E, Bryan C, ... The drug is composed of three monoclonal antibodies (mAbs), initially harvested from mice exposed to Ebola virus proteins, that ... The components are chimeric monoclonal antibody c13C6 from a previously existing antibody cocktail called "MB-003" and two ... Brincidofovir Monoclonal antibody therapy Palivizumab Pre-clinical development TKM-Ebola VSV-EBOV Kroll, David (5 August 2014 ...
"Mining naïve rabbit antibody repertoires by phage display for monoclonal antibodies of therapeutic utility". Journal of ... is a UK biotechnology company that uses a human cell microarray system to identify cell surface receptors for antibodies and ...
February 2010). Zhang L (ed.). "New class of monoclonal antibodies against severe influenza: prophylactic and therapeutic ... CR6261 is a monoclonal antibody that binds to a broad range of the influenza virus including the 1918 "Spanish flu" (SC1918/H1 ... Ekiert DC, Bhabha G, Elsliger MA, Friesen RH, Jongeneelen M, Throsby M, Goudsmit J, Wilson IA (April 2009). "Antibody ... In contrast to most antibodies generated by exposure to influenza, which can only neutralize a few strains from within a single ...
Therapeutic monoclonal antibodies (mAbs) are used for several diseases, including cancer and Rheumatoid arthritis. Consequently ... Although the exact mechanism is unclear, it is suspected that the mAbs are inducing infusion reactions by eliciting antibody ... "Immunogenicity of Innovative and Biosimilar Monoclonal Antibodies". Antibodies. 8 (1): 21. doi:10.3390/antib8010021. PMC ... Monoclonal antibodies, modern vaccines and gene therapy". Pharmacological Reports. 65 (5): 1086-1101. doi:10.1016/s1734-1140(13 ...
Scott, Shane D. (1998). "Rituximab: A New Therapeutic Monoclonal Antibody for Non-Hodgkin's Lymphoma". Cancer Practice. 6 (3): ... Other anti-CD20 monoclonalsEdit. The efficacy and success of Rituximab has led to some other anti-CD20 monoclonal antibodies ... antibody-dependent cellular cytotoxicity).[57] This strategy for enhancing a monoclonal antibody's ability to induce ADCC takes ... Rituximab is a chimeric monoclonal antibody against the protein CD20, which is primarily found on the surface of immune system ...
Mass spectrometry is commonly used to characterize deamidation states of proteins, including therapeutic monoclonal antibodies ... J Biol Chem 266:22549-22556 Zhen, Jing (2018). "Antibody characterization using novel ERLIC-MS/MS-based peptide mapping". mAbs ... This can prove problematic in the case of therapeutic proteins which can be mischaracterized in QC protocols if a large ... "Quantification and characterization of antibody deamidation by peptide mapping with mass spectrometry". International Journal ...
"Therapeutic monoclonal antibody developed in Xuzhou, China for treatment of Alzheimer's disease". Archived from the original on ... Three anti-Aβ42 monoclonal antibodies (Xuzhou 1, 2 and 3) have been developed in 2011 for early detection and treatment of ... "Therapeutic Monoclonal Antibody for Early Detection and Treatment of Alzheimer's Disease Approved by Chinese Academy of ... It has also developed a monoclonal antibody (R813) to human platelet surface glycoprotein IIIa. The Phase I clinical trial has ...
"A Single Tri-Epitopic Antibody Virtually Recapitulates the Potency of a Combination of Three Monoclonal Antibodies in ... "Determining the Binding Affinity of Therapeutic Monoclonal Antibodies towards Their Native Unpurified Antigens in Human Serum ... "Measurement of the functional affinity constant of a monoclonal antibody for cell surface receptors using kinetic exclusion ... "Translational strategies for development of monoclonal antibodies from discovery to the clinic". Drug Discovery Today. 14 (5-6 ...
"US Patent #6,217,866 : Monoclonal antibodies specific to human epidermal growth factor receptor and therapeutic methods ... ImClone's stock price dropped sharply at the end of 2001 when its drug Erbitux, an experimental monoclonal antibody, failed to ... "Monoclonal antibodies specific to human epidermal growth factor receptor and therapeutic methods employing same." "ImClone goes ... Schlessinger testified in court that the idea of combining the anti-EGFR antibody that his lab had developed with chemotherapy ...
"Expression Enhancement in Trastuzumab Therapeutic Monoclonal Antibody Production using Genomic Amplification with Methotrexate ... His PhD research, performed with Mark Greene and Robert Weinberg, involved the creation of monoclonal antibodies targeting the ... "Down-modulation of an oncogene protein product and reversion of the transformed phenotype by monoclonal antibodies". Cell. 41 ( ... Her2/neu protein and demonstrating in preclinical models that such antibodies could inhibit cancer cell growth in vitro and in ...
Therapeutic glycosylated proteins, including monoclonal antibodies and interferon (IFN-alpha2b) have been produced using the ... Glycan optimization of a human monoclonal antibody in the aquatic plant Lemna minor. Nat Biotechnol. 2006 Dec; 24(12): 1591-7. ... Official site Background information on production of therapeutic proteins in 'Lemna'. ... "Advantages of Therapeutic Protein Production in the Aquatic Plant Lemna" BioProcessing Journal, Mar/Apr 2003. Cox KM et al. ...
"Monoclonal antibodies specific for human IgE-producing B cells: a potential therapeutic for IgE-mediated allergic diseases". ... Scientists in Genentech had made a mouse anti-IgE monoclonal antibody with the binding specificity similar to that of CGP51901 ... Thus, therapeutic anti-IgE antibodies such as omalizumab represent a new class of potent mast cell stabilizers. This is now ... Retrieved 2012-06-23.; "Monoclonal antibodies that bind to soluble IGE but do not bind IGE on IGE expressing B lymphocytes or ...
"Monoclonal antibodies specific for human IgE-producing B cells: a potential therapeutic for IgE-mediated allergic diseases". ... the anti-IgE program and other therapeutic antibody programs eventually absorbed all resources Tanox had, and the antibody ... The set of patents pertain to the generation of monoclonal antibodies, especially human monoclonal antibodies, by identifying ... Other than the therapeutic antibodies, which target the IgE allergic pathway, immune factors, and CD4, Tanox also possessed ...
Edrecolomab, catumaxomab and other monoclonal antibodies are designed to bind to it. also nofetumomab. EpCAM is often ... Armstrong A, Eck SL (2003). "EpCAM: A new therapeutic target for an old cancer antigen". Cancer Biology & Therapy. 2 (4): 320-6 ... The diagnosis of such conditions can therefore be assisted by immunohistochemistry using BerEp4, which is an antibody to EpCAM ... Herlyn D, Herlyn M, Steplewski Z, Koprowski H (August 1979). "Monoclonal antibodies in cell-mediated cytotoxicity against human ...
Antibody types[edit]. The antibodies used for specific detection can be polyclonal or monoclonal. Polyclonal antibodies are ... Immunohistochemistry is used to determine patients who may benefit from therapeutic antibodies such as Erbitux (cetuximab).[18] ... Monoclonal antibodies[edit]. Main article: Monoclonal antibody therapy. Many proteins shown to be highly upregulated in ... Thus, polyclonal antibodies are a heterogeneous mix of antibodies that recognize several epitopes. Monoclonal antibodies are ...
The therapeutic usage of monoclonal antibodies against CD32B can be effective for inducing cytotoxicity against B cell lymphoma ... Having too little CD32B has been associated with dysregulated antibody function, as well as increased antibody-dependent ... The usage of monoclonal antibodies can distinguish between CD32A and CD32B; however, the high degree of homology between the ... July 2007). "Monoclonal antibodies capable of discriminating the human inhibitory Fcgamma-receptor IIB (CD32B) from the ...
... (trade name Zinbryta) is a therapeutic humanized monoclonal antibody which was used for the treatment of adults with ... Patients who developed antibodies against daclizumab eliminated it 19% faster. Daclizumab was created by scientists at PDL ... FDA BLA Approval letter May 27, 2016 Lycke J (November 2015). "Monoclonal antibody therapies for the treatment of relapsing- ... March 04, 1999 Roche Press Release: Zenapax (daclizumab), The First Humanized Monoclonal Antibody To Prevent Organ Rejection, ...
IL-23 is one of the therapeutic targets to treat the inflammatory diseases. Ustekinumab, a monoclonal antibody directed against ... Leonard JP, Waldburger KE, Goldman SJ (January 1995). "Prevention of experimental autoimmune encephalomyelitis by antibodies ... Guselkumab is also monoclonal antibody against IL-23. Blocking IL-23 can slow clinical manifestation of psoriasis indirectly ... It is thus a target for therapeutic research. IL-23 expressed by dendritic cells is further induced by thymic stromal ...
"Investigational Monoclonal Antibody to Treat Ebola Is Safe in Adults" (Press release). National Institute of Allergy and ... Researchers looking at slides of cultures of cells that make monoclonal antibodies. These are grown in a lab and the ... "Therapeutic strategies to target the Ebola virus life cycle". Nature Reviews. Microbiology. 17 (10): 593-606. doi:10.1038/ ... IgM antibodies are detectable two days after symptom onset and IgG antibodies can be detected six to 18 days after symptom ...
Anti-TNF monoclonal antibodies *Infliximab. *Adalimumab. *Certolizumab pegol. *Golimumab. References[edit]. *^ Feldmann M, ... It fuses the TNF receptor to the constant end of the IgG1 antibody. First, the developers isolated the DNA sequence that codes ... TNF defined as a therapeutic target for rheumatoid arthritis and other autoimmune diseases". Nature Medicine. 9 (10): 1245-50. ...
... and identified the therapeutic effects of monoclonal anti-TNF antibodies.[20][21] More recently, research in the Laboratory of ... This inhibition can be achieved with a monoclonal antibody such as infliximab (Remicade) binding directly to TNFα, adalimumab ( ... "Anti-cachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteraemia". Nature. 330 (6149): 662-64. Bibcode: ...
... monoclonal antibodies have been shown in experiments with mice to involve ADCC as an important mechanism of therapeutic action. ... Afucosylated monoclonal antibodies. References[edit]. *^ Hashimoto, G.; Wright, P. F.; Karzon, D. T. (1983-11-01). "Antibody- ... a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors". J ... Monoclonal antibody action against cancer[edit]. The effects against solid tumors of trastuzumab and rituximab ...
"Transgenic plants of Nicotiana tabacum L. express aglycosylated monoclonal antibody with antitumor activity". Biotecnologia ... Effects on therapeutic efficacy[edit]. It has been reported that mammalian glycosylation can improve the therapeutic efficacy ... Glycosylation is an important parameter in the optimization of many glycoprotein-based drugs such as monoclonal antibodies.[5] ... Aglycosylation is a feature of engineered antibodies to bypass glycosylation.[2][3] Five classes of glycans are produced: *N- ...
1c) Monoclonal antibody drug uses a different subset of parameters, defining the parameter type=mab. This allows the ... The MAB name has appended after it a "?" linked to Nomenclature of monoclonal antibodies, saving on the need explain how each ... Shortened Monoclonal antibody form: {{Drugbox , type = mab , image = , source = ,!-- organism from which derived --, , target ... Full Monoclonal antibody template with extended fields: {{Drugbox , type = mab , image = , width = , image2 = , width2 = , ...
Antibodies. *Antibody *Monoclonal antibodies. *Polyclonal antibodies. *Autoantibody. *Microantibody. *Polyclonal B cell ... so transfusion of granulocytes as a therapeutic strategy would confer a very short-lasting benefit. In addition, there are many ... secretions from the primary granules of neutrophils stimulate the phagocytosis of IgG antibody-coated bacteria.[14] The ... they are ferocious eaters and rapidly engulf invaders coated with antibodies and complement, as well as damaged cells or ...
An extensive panel of monoclonal antibodies to cell surface markers, particularly CD or cluster of differentiation markers, are ... Blinatumomab, a CD19-CD3 bi-specific monoclonal murine antibody, currently shows promise as a novel pharmacotherapy. By ... The evidence is very uncertain about the therapeutic effect of mesenchymal stromal cells to treat graft-versus-host diseases ... In this therapy, mice are immunized with the CD19 antigen and produce anti-CD19 antibodies. Hybridomas developed from mouse ...
Antibodies. *Antibody *Monoclonal antibodies. *Polyclonal antibodies. *Autoantibody. *Microantibody. *Polyclonal B cell ... Nikoopour E, Schwartz JA, Singh B (2008). "Therapeutic benefits of regulating inflammation in autoimmunity". Inflamm Allergy ... Idiotype Network theory, proposed by Jerne, wherein a network of antibodies capable of neutralizing self-reactive antibodies ... 2002) injected an anti-MHC Class II antibody into mice expressing a single type of MHC Class II molecule (H-2b) to temporarily ...
CI monoclonal antibodies ("-mab"). Receptor tyrosine kinase. *ErbB: HER1/EGFR (Cetuximab. *Panitumumab) ... Antibody-drug conjugates[edit]. Antibody-drug conjugates (ADCs) comprise an antibody, drug and a linker between them. The ... Therapeutic agents". Dermatologic Clinics. 16 (2): 341-356. PMID 9589208. doi:10.1016/S0733-8635(05)70017-6.. ... Sievers EL, Linenberger M (Nov 2001). "Mylotarg: antibody-targeted chemotherapy comes of age". Current Opinion in Oncology. 13 ...
... these antibodies are called monoclonal antibodies.[69] Polyclonal and monoclonal antibodies are often purified using Protein A/ ... "Alternative molecular formats and therapeutic applications for bispecific antibodies". Molecular Immunology. 67 (2): 95-106. ... monoclonal antibodies are identical antibodies produced by a single B cell.. Asymmetrical antibodies[edit]. Heterodimeric ... Antibody mimetic[edit]. Antibody mimetics are organic compounds that, like antibodies, can specifically bind antigens. They are ...
Idarucizumab is a monoclonal antibody, approved by the US FDA in 2015, that reverses effect of dabigatran by binding to both ... "Therapeutic Advances in Cardiovascular Disease. 11 (9): 243-256. doi:10.1177/1753944717714921. PMC 5562140. PMID 28651452.. ... Pathogenesis of immune-mediated HIT is believed to be caused by heparin-dependent immunoglobulin antibodies binding to platelet ... The antithrombin protein itself is used as a protein therapeutic that can be purified from human plasma[104] or produced ...
It was constructed from a fully human monoclonal antibody, while infliximab is a mouse-human chimeric antibody and etanercept ... Brekke OH, Sandlie I (January 2003). "Therapeutic antibodies for human diseases at the dawn of the twenty-first century". Nat ... Adalimumab was the first fully human monoclonal antibody approved by the US Food and Drug Administration (FDA).[34] It was ... 1999: Preliminary results of early clinical trials with the fully human anti-TNFα monoclonal antibody D2E7[37] ...
... an anti-LAG3 monoclonal antibody that is currently in phase 1 clinical testing.[24] A number of additional LAG3 antibodies are ... Triebel F (Dec 2003). "LAG-3: a regulator of T-cell and DC responses and its use in therapeutic vaccination". Trends in ... Combination therapies are also ongoing involving LAG-3 antibodies and CTLA-4 or PD-1 antibodies.[8] ... The second are antibodies to LAG3 which take the brakes off the anti-cancer immune response.[8] An example is relatlimab, ...
Nicolas JF, Reano A, Kaiserlian D, Thivolet J.,Epithelial cell heterogeneity in mammalian thymus: monoclonal antibody to high ... immunohistochemical characterization of four thymic epithelial subsets defined by monoclonal anti-keratin antibodies., Eur J ... "Thymus Gland Pathology: Clinical, Diagnostic and Therapeutic Features", Corrado Lavini,1. Peatükk: The thymus from antiquity ... A unique thymic fibroblast population revealed by the monoclonal antibody MTS-15., J Immunol. 15. aprill 2007;178(8):4956-65., ...
Monoclonal antibodies targeting both PD-1 and PD-L1, such as pembrolizumab, nivolumab,[183] atezolizumab, and durvalumab[182] ... Denosumab is a monoclonal antibody directed against receptor activator of nuclear factor kappa-B ligand. It may be useful in ... "Therapeutic Advances in Medical Oncology. 6 (3): 101-114. doi:10.1177/1758834014521110. PMC 3987652 . PMID 24790650.. ... For therapeutic purposes, two broad classes are distinguished: non-small-cell lung carcinoma and small-cell lung carcinoma.[66] ...
A study called BLISS-76 tested the drug belimumab, a fully human monoclonal anti-BAFF (or anti-BLyS) antibody.[85] BAFF ... These antibodies clump into antibody-protein complexes which stick to surfaces and damage blood vessels in critical areas of ... Pan HF, Wu GC, Li WP, Li XP, Ye DQ (February 2009). "High Mobility Group Box 1: a potential therapeutic target for systemic ... Subtypes of antinuclear antibodies include anti-Smith and anti-double stranded DNA (dsDNA) antibodies (which are linked to SLE ...
... is human or nonhuman blood serum containing monoclonal or polyclonal antibodies that is used to spread passive ... "Humanized Cobra Venom Factor: Structure, Activity, And Therapeutic Efficacy In Preclinical Disease Models." Molecular ... immunity to many diseases via blood donation (plasmaphoresis). For example, convalescent serum, passive antibody transfusion ... Antibodies in the antiserum bind the infectious agent or antigen.[8] The immune system then recognizes foreign agents bound to ...
The monoclonal antibody figitumumab which targets the IGF-1R is currently undergoing clinical trials.[24][25] ... Commencing treatment with a number of different therapeutic agents with differing modes of action is thought to provide the ... Antibodies: Against TrkA: GBR-900; Against NGF: ABT-110 (PG110). *ASP-6294 ...
... of different antibodies on phage are often used in the pharmaceutical industry to isolate highly specific therapeutic antibody ... "A large array of human monoclonal antibodies to type 1 human immunodeficiency virus from combinatorial libraries of ... Antibody phage display was later used by Carlos F. Barbas at The Scripps Research Institute to create synthetic human antibody ... Adalimumab, an antibody to TNF alpha, was the world's first fully human antibody, which achieved annual sales exceeding $1bn. ...
... is a therapeutic antibody that binds to and blocks PD-1 located on lymphocytes. This receptor is generally ... Buqué, Aitziber (April 2015). "Trial Watch: Immunomodulatory monoclonal antibodies for oncological indications". Oncoimmunology ... and people with a history of severe reaction to another monoclonal antibody.[needs update] People have had severe infusion- ... It is an IgG4 isotype antibody that blocks a protective mechanism of cancer cells and thereby, allows the immune system to ...
... microarray hybridization data Yeast two-hybrid screen Monoclonal antibodies such as mouse anti-human Duox2 monoclonal antibody ... "Therapeutic anti-IgE monoclonal antibody single chain variable fragment (scFv) safety and immunomodulatory effects after one ... "Creative Biolabs Updates Its Antibody Humanization Service to Further Accelerate Your Monoclonal Antibody Research". EIN ... "Creative Biolabs Announces A Successful Completion Of Virbac's Unique Monoclonal Antibody Discovery Project Through Cooperation ...
Typically, the antibody used for this experiment is the anti-estrogen Receptor (ER) (SP1) Rabbit Monoclonal Antibody. Employing ... The IHC analysis was then performed the same day using anti-ER monoclonal antibodies, and resulted in a consistently strong ... Predictive biomarker assays seem to be the golden standard for therapeutic interventions of today as they allow insight to the ... Anti-estrogen receptor antibodies were among the first of biomarkers which introduced a semi-quantitative assessment of the ER ...
... "been central to the development of the Moderna mRNA vaccine and the Eli Lilly therapeutic monoclonal antibody that were first ... For her doctoral work, Corbett worked in Sri Lanka to study the role of human antibodies in dengue virus pathogenesis. While in ... From 2009 to 2014, Corbett studied human antibody responses to dengue virus in Sri Lankan children under the supervision of ... Kizzy Corbett Day". Corbett, Kizzmekia Shanta (August 2014). Characterization of Human Antibody Responses to Dengue Virus ...
Rituximab, a monoclonal antibody directed against and killing CD20-expressing cells, appears to improve the efficacy of ... Cases associated with HIV/AIDS test positive for antibodies directed against this virus. (PEL occurs in the absence of HHV-8 ... Rubinstein PG, Aboulafia DM, Zloza A (February 2014). "Malignancies in HIV/AIDS: from epidemiology to therapeutic challenges". ... One factor that appears to improve the treatment of Type II PEL is the addition of rituximab (a monoclonal antibody directed ...
They can involve monoclonal antibodies such as bevacizumab, antibody derivatives such as ranibizumab (Lucentis), or orally- ... Bergers and Hanahan concluded in 2008 that anti-VEGF drugs can show therapeutic efficacy in mouse models of cancer and in an ... Ranibizumab, a monoclonal antibody fragment (Fab) derived from bevacizumab, has been developed by Genentech for intraocular use ... Some of these therapies target VEGF receptors rather than the VEGFs.) Both antibody-based compounds and the first three orally ...
... which can be targeted at tumours by aid of monoclonal antibodies: DOTA-biotin DOTA linked to the monoclonal antibody ... Volkert, Wynn A.; Timothy J. Hoffman (1999). "Therapeutic Radiopharmaceuticals". Chemical Reviews. 99 (9): 2269-2292. doi: ... DOTA can be conjugated to monoclonal antibodies by attachment of one of the four carboxyl groups as an amide. The remaining ... "Pre-targeted radioimmunotherapy of human colon cancer xenografts in athymic mice using streptavidin-CC49 monoclonal antibody ...
... are antibodies of a single antigen specificity produced by identical immune cells, i.e., clones of a common germ cell. They ... Scott SD (1998) Rituximab: a new therapeutic monoclonal antibody for non-Hodgkins lymphoma. Cancer Pract 6:195-197PubMed ... Chimeric monoclonal antibodies Crohns disease Fully human monoclonal antibodies Humanized monoclonal antibodies Hybridoma ... Therapeutic Human Monoclonal Antibodies in Inflammatory Diseases. In: Steinitz M. (eds) Human Monoclonal Antibodies. Methods in ...
... antibody‐producing cells from immunised animals with cells that confer immortality and high‐yield antibody production) or by ... Monoclonal antibodies are protein molecules madein the laboratory from hybridoma cells (stable cell lines derived by fusing ... Therapeutic monoclonal antibodies can be engineered to be more human‐like proteins, to increase their affinity, reduce their ... Monoclonal antibodies can be produced in large amounts in homogeneous and reproducible form for diagnostic and therapeutic ...
... indicating a possible participation of specific antibodies to this molecule in infection control. In an other work of the our ... The strong protection induced by mAb against a 70-kDa glycoprotein makes it a strong candidate for a therapeutic vaccine ... indicating a possible participation of specific antibodies to this molecule in infection control. In an other work of the our ... Therapeutic Monoclonal Antibodies and Fungal Infection. Monoclonal antibodies are attractive biologic drugs because of their ...
... a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics, announced that they have ... the industry leader in the discovery of monoclonal antibodies (MAbs) against membrane proteins, and Merus N.V. (Nasdaq:MRUS), ... integral-molecular-partners-with-merus-to-discover-novel-therapeutic-monoclonal-antibodies/. More in Biology. * Scientists have ... Integral Molecular partners with Merus to discover novel therapeutic monoclonal antibodies New discovery collaboration ...
Monoclonal antibodies that strongly neutralized WNV localized to a surface patch on the lateral face of domain III. ... One monoclonal antibody, E16, neutralized 10 different strains in vitro, and showed therapeutic efficacy in mice, even when ... Development of a humanized monoclonal antibody with therapeutic potential against West Nile virus.. Oliphant T1, Engle M, ... Development of a Humanized Monoclonal Antibody with Therapeutic Potential against West Nile Virus ...
70-chapter authoritative reference that covers therapeutic monoclonal antibody discovery, development, and clinical app... ... Read Therapeutic Monoclonal Antibodies From Bench to Clinic by with Rakuten Kobo. ... 70-chapter authoritative reference that covers therapeutic monoclonal antibody discovery, development, and clinical ... First book to address the discovery and development of antibody therapeutics in their entirety. ...
Abstract: Therapeutic monoclonal antibodies (mAbs) including antibody fusion proteins and antibody conjugates present an ... Therapeutic monoclonal antibodies (mAbs) including antibody fusion proteins and antibody conjugates present an innovative class ... Safety of Therapeutic Monoclonal Antibodies. Author(s): Ronald Niebecker, Charlotte Kloft. Department of Clinical Pharmacy, ... Keywords:Monoclonal antibodies, antibody fusion proteins, drug safety, adverse drug reaction (ADR), immunogenicity, human anti- ...
... and the potential of monoclonal antibodies (mAbs) for the treatment of MS has been highlighted. Natalizumab demonstrated a high ... Any therapeutic agents for MS may carry risks of short- or long-term side effects; however, information regarding the long-term ... Therapeutic application of monoclonal antibodies in multiple sclerosis: focus on alemtuzumab Masaaki NiinoDepartment of ... monoclonal antibody, alemtuzumab, therapy, experimental autoimmune encephalomyelitis ...
See the list of FDA-approved therapeutic monoclonal antibodies in the monoclonal antibody therapy page. "United Therapeutics 10 ... This is a list of therapeutic, diagnostic and preventive monoclonal antibodies, antibodies that are clones of a single parent ... single-domain antibody BsMAb: bispecific monoclonal antibodies: 3funct: trifunctional antibody BiTE: bi-specific T-cell engager ... The remaining syllables of the INNs, as well as the column Source, are explained in Nomenclature of monoclonal antibodies. The ...
Herman Waldmann on Monoclonal antibodies to induce therapeutic immunological tolerance, part of a collection of multimedia ... Monoclonal antibodies to induce therapeutic immunological tolerance. *Prof. Herman Waldmann - University of Oxford, UK ... Monoclonal antibodies to induce therapeutic immunological tolerance. Embed in course/own notes ... Waldmann, H. (2019, April 30). Monoclonal antibodies to induce therapeutic immunological tolerance [Video file]. In The ...
Trastuzumab (herceptin) is a humanized IgG1 kappa monoclonal antibody (mAb). The antibody was obtained through genetic ... Advantages of Online Two-Dimensional Chromatography for MRM Quantification of Therapeutic Monoclonal Antibodies in Serum. ... Advantages of Online Two-Dimensional Chromatography for MRM Quantification of Therapeutic Monoclonal Antibodies in Serum ... A stock solution of trastuzumab (150 kDa monoclonal antibody) was spiked with the internal standard (13C15N-isotopically ...
A therapeutic monoclonal antibody, infliximab, was used as a model protein to evaluate the functionality. ... A therapeutic monoclonal antibody, infliximab, was used as a model protein to evaluate the functionality. ... A therapeutic monoclonal antibody, infliximab, was used as a model protein to evaluate the functionality. ... Charge Variant Analysis of Therapeutic Monoclonal Antibodies Using a pH Gradient Generated by Auto•Blend Plus. Charge Variant ...
This preclinical study suggests that anti-EpCAM antibody conjugates with α-amanitin have the potential to be highly effective ... therapeutic agents for pancreatic carcinomas and various EpCAM-expressing malignancies. ... Anti-EpCAM antibodies have shown promise in preclinical studies, but showed no tumor regression in a recent phase II clinical ... Therapeutic potential of amanitin-conjugated anti-epithelial cell adhesion molecule monoclonal antibody against pancreatic ...
... in therapeutic proteins. The method utilizes a mixed-mode chromatography column and a step gradient of formic acid and ... bispecific antibodies, antibody drug conjugates (ADCs), and bispecific ADCs, thereby establishing a truly selective method free ... A universal method for the determination of polysorbate 80 in monoclonal antibodies and novel protein therapeutic formulations ... A universal method for the determination of polysorbate 80 in monoclonal antibodies and novel protein therapeutic formulations ...
We recently described the development of a novel humanized monoclonal antibody that targets uPAR and has anti-tumor activity in ... This antibody, ATN-658, does not inhibit ligand binding (i.e. uPA and vitronectin) to uPAR and its mechanism of action remains ... functional epitope on uPAR involved in tumor progression and demonstrate a previously unrecognized strategy for the therapeutic ... supernatants from these monoclonal antibodies were then assayed for activity in ELISA assays and the isotype of each antibody ...
Session I: ANTIBODIES AND NON-ISOTOPIC IMMUNOCONJUGATES. *. Targeting Endothelial Growth with Monoclonal Antibodies against Tie ... Therapeutic Potential of Chimeric Amyloid-reactive Monoclonal Antibody 11-1F4. Alan Solomon, Deborah T. Weiss and Jonathan S. ... Therapeutic Potential of Chimeric Amyloid-reactive Monoclonal Antibody 11-1F4. Alan Solomon, Deborah T. Weiss and Jonathan S. ... Therapeutic Potential of Chimeric Amyloid-reactive Monoclonal Antibody 11-1F4. Alan Solomon, Deborah T. Weiss and Jonathan S. ...
Monoclonal antibodies have become a mainstay for the targeted treatment of cancer today. Some of the most successful targets of ... Home » Therapeutic Targeting of Lewisy and Lewisb with a Novel Monoclonal Antibody 692/29 ... Therapeutic Targeting of Lewisy and Lewisb with a Novel Monoclonal Antibody 692/29. ... Background: Several monoclonal antibodies (mAbs) recognising Lewisy, such as BR96, have reached the clinic but have failed to ...
... of neonatal immune tolerance induction in mice to enable long-term pharmacokinetic studies with immunogenic therapeutic ... Elimination mechanisms of therapeutic monoclonal antibodies. Drug Discov Today. 2006;11:81-8.CrossRefPubMedGoogle Scholar ... For most therapeutic proteins, including monoclonal antibodies (mAb), ADA formation increases clearance (3, 4, 5); for smaller ... Neonatal Immune Tolerance Induction to Allow Long-Term Studies With an Immunogenic Therapeutic Monoclonal Antibody in Mice. ...
... confers resistance to therapeutic anti-CD137 antibody in mice with established tumors. The resistance is accompanied with ... Blockade of B7-H1 and PD-1 by Monoclonal Antibodies Potentiates Cancer Therapeutic Immunity. Fumiya Hirano, Katsumi Kaneko, ... Blockade of B7-H1 or PD-1 by specific monoclonal antibodies could reverse this resistance and profoundly enhance therapeutic ... Blockade of B7-H1 and PD-1 by Monoclonal Antibodies Potentiates Cancer Therapeutic Immunity ...
... including therapeutic monoclonal antibodies (TMAs). The plant monoclonal antibody production platform has attracted researchers ... Monoclonal antibody Immunoglobulin G Antibody N-glycosylation Therapeutic antibody Immunotherapy Plant viruses Transient ... Therapeutic monoclonal antibody N-glycosylation - Structure, function and therapeutic potential. Journal of ... Dorokhov Y.L., Sheshukova E.V., Komarova T.V. (2019) Plant Platform for Therapeutic Monoclonal Antibody Production. In: Khurana ...
9.6 Million in Series A Financing to Fund Its Therapeutic Monoclonal Antibody Product Pipeline MONTREAL, QUEBEC--(Marketwire - ... Monoclonal antibodies that specifically target SIGLEC-15, a cell surface protein that is stimulated during early osteoclast ... Alethia Biotherapeutics Secures C$9.6 Million in Series A Financing to Fund Its Therapeutic Monoclonal Antibody Product ... Alethia Biotherapeutics Secures C$9.6 Million in Series A Financing to Fund Its Therapeutic Monoclonal Antibody Product ...
Successful treatment of Ebola virus-infected cynomolgus macaques with monoclonal antibodies. Sci. Transl. Med. 4, 138ra81 (2012 ... Therapeutic Intervention of Ebola Virus Infection in Rhesus Macaques with the MB-003 Monoclonal Antibody Cocktail ... Therapeutic Intervention of Ebola Virus Infection in Rhesus Macaques with the MB-003 Monoclonal Antibody Cocktail ... Therapeutic Intervention of Ebola Virus Infection in Rhesus Macaques with the MB-003 Monoclonal Antibody Cocktail ...
Monoclonal antibodies in the management of newly diagnosed, aggressive B-cell lymphoma. Curr. Hematol. Rep. 2: 23-29. ... Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcγRIIIa gene. Blood 99: ... Daratumumab, a Novel Therapeutic Human CD38 Monoclonal Antibody, Induces Killing of Multiple Myeloma and Other Hematological ... Daratumumab, a Novel Therapeutic Human CD38 Monoclonal Antibody, Induces Killing of Multiple Myeloma and Other Hematological ...
This application note describes a fast and high-resolution method for the analysis of intact and reduced therapeutic innovator ... Therapeutic monoclonal antibodies (mAbs) have become the most rapidly growing class of therapeutics in development for many ... How to analyze antibody internalization in real-time using live-cell... Watch Now ... Therapeutic monoclonal antibodies (mAbs) have become the most rapidly growing class of therapeutics in development for many ...
Monoclonal antibodies are currently in clinical development or undergoing clinical trials to treat COVID-19. Further clinical ... a humanized therapeutic monoclonal antibody to the IL-6 receptor (IL-6R), for hospitalized patients with moderate and severe ... In 2011, a humanized monoclonal antibody to the IL-6 receptor (IL-6R), tocilizumab, was approved by the US Food and Drug ... Editorial: Tocilizumab, a Humanized Therapeutic IL-6 Receptor (IL-6R) Monoclonal Antibody, and Future Combination Therapies for ...
... are therapeutic monoclonal antibodies. This rapid growth in demand for monoclonal antibody production has been well ... the therapeutic market for monoclonal antibodies has grown exponentially. In 2006, the "big 5" therapeutic antibodies on the ... Monoclonal antibody therapy is a form of immunotherapy that uses monoclonal antibodies (mAb) to bind monospecifically to ... Antigen 5T4 Immunotherapy Immunoconjugate Nomenclature of monoclonal antibodies List of monoclonal antibodies, including ...
  • Monoclonal antibodies (mAbs) are antibodies of a single antigen specificity produced by identical immune cells, i.e., clones of a common germ cell. (
  • Integral Molecular, the industry leader in the discovery of monoclonal antibodies (MAbs) against membrane proteins, and Merus N.V. (Nasdaq:MRUS), a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics, today announced. (
  • Integral Molecular, the industry leader in the discovery of monoclonal antibodies (MAbs) against membrane proteins, and Merus N.V. (Nasdaq:MRUS), a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics, announced that they have entered into a collaboration on multiple undisclosed targets. (
  • Many of these MAbs are the first of their kind to be isolated, as complex membrane proteins have historically been extremely difficult targets for antibody discovery. (
  • Therapeutic monoclonal antibodies (mAbs) including antibody fusion proteins and antibody conjugates present an innovative class of (bio-)pharmaceuticals with increasing clinical importance. (
  • As more mAbs appear on the market, characteristics of their safety profiles become apparent, including immunogenicity, i.e. the potential induced formation of human anti-drug antibodies (HADAs) in patients. (
  • In conclusion, mAbs are generally safe but as they may be associated with significant ADRs, the individual risks need to be weighed against the expected therapeutic benefit. (
  • Recent progress in the treatment of multiple sclerosis (MS) is significant, and the potential of monoclonal antibodies (mAbs) for the treatment of MS has been highlighted. (
  • We had previously reported that certain of our murine (m) antihuman light chain monoclonal antibodies (mAbs) recognized an epitope common to AL and other types of amyloid fibrils. (
  • Background: Several monoclonal antibodies (mAbs) recognising Lewisy, such as BR96, have reached the clinic but have failed to show good anti-tumour responses with an acceptable level of toxicity. (
  • Conclusions/Significance: MAbs targeting both Lewisy and Lewisb may have a therapeutic advantage over mAbs targeting just one hapten. (
  • MONTREAL, QUEBEC--(Marketwire - Sept. 7, 2010) - Alethia Biotherapeutics Inc., a privately held Montreal-based biopharmaceutical company focused on the development of monoclonal antibodies ("mAbs") against therapeutic targets emanating from its STAR proprietary target discovery platform, announced today it has closed a C$9.6M Series A round of financing. (
  • We believe Alethia's very sensitive proprietary target discovery platform favorably positions the company for building an excellent pipeline of therapeutic mAbs and forming strategic alliances," said Elizabeth Douville from AgeChem. (
  • Therapeutic monoclonal antibodies (mAbs) have become the most rapidly growing class of therapeutics in development for many diseases. (
  • This application note describes a fast and high-resolution method for the analysis of intact and reduced therapeutic innovator and biosimilar mAbs by reverse phase high performance liquid chromatography. (
  • Zhang et al 6 investigated the potential of anti-HBsAg monoclonal antibodies (mAbs) infusion for clearance of circulating HBsAg in chronic infection. (
  • A key step in bioprocess development for monoclonal antibodies (mAbs) involves optimization and control of N-glycan profiles. (
  • Therapeutic monoclonal antibodies (MAbs) are an important class of drugs used to treat diseases ranging from autoimmune disorders to B cell lymphomas to other rare conditions thought to be untreatable in the past. (
  • The rise in the use of therapeutic MAbs has opened up new challenges for the development of assays for monitoring this class of drugs. (
  • MAbs are larger and more complex than typical small-molecule therapeutic drugs routinely analyzed by mass spectrometry. (
  • In contrast to an enzyme-linked immunosorbent assay (ELISA) for quantifying MAbs, mass spectrometry-based assays do not rely on MAb-specific reagents such as recombinant antigens and/or anti-idiotypic antibodies, and time for development is usually shorter. (
  • This poses an opportunity for the clinical laboratory to develop a new niche of tests and improve patient care by personalizing therapeutic regimens with MAbs. (
  • Therapeutic MAbs are typically modeled after human immunoglobulins (Igs), homodimers with a molecular mass of approximately 150 kDa. (
  • It is critical to understand the relationship between the constant region and the variable region of Igs and therefore therapeutic MAbs. (
  • Therapeutic MAbs currently on the market are predominately IgG1 kappa, with a few being IgG2, IgG4, or hybrids. (
  • International nonproprietary names (INNs) have been assigned to MAbs since 1991 and use -MAb as a stem and specific substems to cover their source (-omab for murine, -ximab for chimeric, -zumab for humanized, and -umab for human antibodies). (
  • Monoclonal antibodies (MAbs) to the polysaccharide capsule are potential therapeutic reagents for use in C. neoformans infections. (
  • Today, there are a wide range of biopharmaceutical formats and the fastest and largest growing class are monoclonal antibodies (mAbs) (2). (
  • In January 2017, there were 68 mAbs approved by the FDA for therapeutic use, and many more mAb products are currently in advanced clinical trials phases (3). (
  • Most of the clinically available monoclonal antibody (mAbs) drugs are Immunoglobulin G's (IgG's). (
  • Monoclonal antibodies (MAbs) are produced from a single B cell clone and can bind to a single type of antigen binding site. (
  • MAbs are homogenous antibodies that cannot form lattices with monomeric proteins as they can bind to only a single epitope on the antigen. (
  • Monoclonal antibodies (mAbs) represent one of the fastest growing classes of drugs in the pharmaceutical industry. (
  • Monoclonal antibodies' (mAbs) elegant specificity has catapulted them to a starring role within the world of precision medicine over the course of the last couple of decades. (
  • Since 1986, more than 70 mAbs, serving either therapeutic or diagnostic purposes, have been approved. (
  • Before diving into the discussion of the benefits, challenges and exciting future of mAbs, it's worth taking a moment to reflect on merely one aspect of the near magical intricacy of antibodies. (
  • mAbs bind monospecifically to one antigen, one epitope, or one cell type making them incredibly useful for highly targeted therapeutic administration. (
  • Host antibodies against EBOV are critical for controlling disease, and recombinant monoclonal antibodies (mAbs) can protect from infection. (
  • Thus, to understand the antibody features mediating EBOV protection, we examined specific Fc features associated with protection using a library of EBOV-specific mAbs. (
  • Monoclonal antibodies (MABs) have become a mainstay of MS treatment and they are likely to continue to be developed for the treatment of this disease. (
  • Monoclonal antibodies (MABs) are one of the preferred treatments for multiple sclerosis (MS) due to their target specificity and usually high efficacy [ 1 ]. (
  • Therapeutic MABs were originally developed from non-human species such as mice. (
  • Reactions to murine MABs were soon associated with the development of antidrug antibodies (ADAs) against the murine-based protein with repeated exposures [ 4 ]. (
  • In order to reduce the potential immunogenicity of murine MABs, chimeric mouse-human antibodies were developed ( Figure 1 ). (
  • Biotech therapeutics, particularly complex products such as monoclonal antibodies (mAbs), can have numerous quality attributes that can potentially impact safety and/or efficacy of the product (2). (
  • Broadly neutralizing human monoclonal antibodies (mAbs) directed against the HCV E2 glycoprotein (HCV/E2), the major target of the neutralizing humoral immune response, are considered as a possible novel therapeutic strategy for this infection. (
  • In the last few years, several anti-HCV/E2 human mAbs have been described in literature to be possibly used for therapeutic or prophylactic purposes. (
  • Monoclonal antibodies have a clear regulatory path for their approval as therapeutics. (
  • First book to address the discovery and development of antibody therapeutics in their entirety. (
  • Yoon, Seongkyu 2016-10-01 00:00:00 The N-linked glycan profiles on recombinant monoclonal antibody therapeutics significantly affect antibody biological functions and are largely determined by host cell genotypes and culture conditions. (
  • The variability in the stability, flexibility, mediation of antibody dependent cell cytotoxicity (ADCC), mediation of cellular dependent cytotoxicity (CDC), and C1q protein binding are major factors that determine the suitability of IgG subclasses for the development of therapeutics. (
  • The variation in stability of different types of immunoglobulin G sub classes affect their suitability in the development of therapeutic monoclonal antibodies, the subject of discussion in this review is the best immunoglobulin G for the development of therapeutics monoclonal antibodies. (
  • Our SuperHuman-2.0 antibody library was computationally optimized for both sequence diversity and engineering fitness through the analysis of thousands of human antibody repertoires and all known monoclonal therapeutics in human phase trials. (
  • Antibodies have been used for antigen detection and therapeutics, and their specificity combined with low toxicity make them a promising pharmaceutical commodity [ 1 ]. (
  • Therapeutic efficacy of the lead hMabs will be determined within Aim 2 in a mouse model of SEB-induced toxic shock to identify a short list of lead therapeutics. (
  • Convalescent antibodies from individuals who had recovered from WNV infection also detected this epitope. (
  • These studies reveal a new functional epitope on uPAR involved in tumor progression and demonstrate a previously unrecognized strategy for the therapeutic targeting of uPAR. (
  • These patents are US# 8,101,726 "Ligands binding the complex of urokinase type plasminogen activator (uPA) and its receptor (uPAR) that inhibit downstream uPAR interactions: identification and use in diagnosis or therapy" (Parry and Mazar) and US# 8,105,602 "Urokinase type plasminogen activator receptor epitope, monoclonal antibodies derived therefrom and methods of use thereof" (Parry and Mazar). (
  • In this study, we describe the cytotoxic mechanisms of action of daratumumab, a novel, high-affinity, therapeutic human mAb against a unique CD38 epitope. (
  • Monoclonal antibodies have monovalent affinity, in that they bind to the same epitope. (
  • The antibody response was diverse in gene usage and epitope recognition. (
  • It provides for the production of multiple monoclonal antibodies, each targeting an immutable epitope for the administration of combination therapy. (
  • 1. A monoclonal antibody produced by hybridoma cell line 7E11-C5, ATCC Designation HB 10494, which monoclonal antibody binds specifically to an epitope present on a membrane associated antigen of human prostatic cancer epithelium and normal prostatic epithelium and which does not bind to non-prostatic antigens present in other tissues. (
  • In cancer immunotherapy, effective therapeutic Abs are typically thought to require both cytostatic and cytotoxic abilities ( 9 ). (
  • The growing trend of implementing immunotherapy into oncology has resulted in various new therapeutic cancer treatments utilizing antibodies. (
  • Immunotherapy with IL2, GM-CSF, and an anti-disialoganglioside (GD2) antibody significantly increases event-free survival in children with high-risk neuroblastoma. (
  • However, the addition of immunotherapy with IL2, GM-CSF, an anti-disialoganglioside (GD2) antibody combined with cis -retinoic acid significantly extends event-free survival in these patients and is now the standard of care ( 3 ). (
  • Therefore, an overview of novel immunological agents and combined therapeutic approaches is presented in this review, covering allogenic and autologous vaccine strategies, dendritic cell vaccination, strategies for adoptive immunotherapy and T cell receptor gene transfer, treatment with cytokines and monoclonal antibodies against the CTLA-4 antigen. (
  • Monoclonal antibodies capable of reacting with membrane associated surface antigens are of value for the immuno-classification and detection of disease and represent novel agents for immunotherapy. (
  • Once cloned, cell lines can be maintained continuously to produce an unlimited homogeneous monoclonal antibody population that can be isolated and/or purified and used clinically for in vitro immunohistological, immuno-cytological or immuno-serological diagnosis, in vivo diagnosis by localization of tumors and metastases, and immunotherapy of human cancers, particularly those of the prostate. (
  • Monoclonal antibody therapy is a form of immunotherapy that uses monoclonal antibodies (mAb) to bind monospecifically to certain cells or proteins. (
  • Immunotherapy developed in the 1970s following the discovery of the structure of antibodies and the development of hybridoma technology, which provided the first reliable source of monoclonal antibodies. (
  • Monoclonal antibodies are proteins with high specificity towards targets. (
  • Therapeutic monoclonal antibodies can be engineered to be more human‐like proteins, to increase their affinity, reduce their immunogenicity and increase their half‐life in the circulation, and can be conjugated with toxin for better lytic effect. (
  • Using the MPS platform, Integral Molecular has discovered antibody assets targeting membrane proteins important in oncology (Claudin 6) and metabolic diseases (CB1, GLUT4), among others. (
  • Integral Molecular's technologies are uniquely suited for discovering diverse antibodies against complex membrane proteins, which are the most compelling targets for treating disease," said Ross Chambers, VP of Antibody Discovery at Integral Molecular. (
  • Quantification of therapeutic proteins in serum without analyte pre-fractionation can offer some advantages in terms of reducing the assay costs and simplifying the sample preparation workflow. (
  • The antibody was obtained through genetic engineering6, 7 by joining the constant regions of the human monoclonal antibody with the complementarity-determining regions (CDRs) of a mouse monoclonal antibody able to bind human epidermal growth factor receptor 2 proteins (HER2) receptors. (
  • Blend Plus Technology uses the ACQUITY UPLC H-Class System's quaternary solvent manager to blend individual pure solutions and concentrated stocks from the reservoirs to deliver pH gradients for the separations of charge variants in therapeutic proteins. (
  • An evaporative light scattering detector (ELSD) based HPLC method that requires minimal sample preparation has been developed to quantitate polysorbate 80 (PS80) in therapeutic proteins. (
  • Plant cells have protein synthesis and post-translational modification (glycosylation and phosphorylation) mechanisms similar to those of animal cells therefore the development of biotechnology allows considering plants as factories for therapeutic proteins, including therapeutic monoclonal antibodies (TMAs). (
  • Modern methods for the production of therapeutic proteins are based on stably transformed transgenic plants and the transient expression of foreign genes. (
  • Production of therapeutic proteins in the chloroplast of Chlamydomonas reinhardtii . (
  • Although well established, this technology is laborious, and it is biased by the experimental animal immune system, which limits the ability to reach a high-affinity antibody against conserved mammal proteins. (
  • Additionally, the heterologous character of those proteins turn them often immunogenic to humans eliciting HAMA response (Human Anti-Mouse Antibodies), which restrict their therapeutic use [ 5 ]. (
  • Like most infections and certain inflammatory diseases, some therapeutic proteins cause a cytokine-mediated suppression of hepatic drug-metabolizing enzymes, which may lead to pharmacokinetic interactions with small-molecule drugs. (
  • We propose a new in vitro method to evaluate the whole blood-mediated effects of therapeutic proteins on drug-metabolizing enzymes in human hepatocytes cocultured with Kupffer cells. (
  • The results demonstrated that applying plasma from human blood treated with a therapeutic protein to hepatocytes cocultured with Kupffer cells is a suitable method to identify those therapeutic proteins that suppress P450 expression by an indirect mechanism-namely, the release of cytokines from PBMCs. (
  • Small-molecule drugs and therapeutic proteins are frequently coadministered to patients with cancer or immune-mediated inflammatory disease such as rheumatoid arthritis. (
  • A hybridoma cell line is disclosed that secretes monoclonal antibodies which serve as a high titer, reproducible, biological reagent useful in biological/medical research for isolating and identifying phosphotyrosine-containing proteins. (
  • 1. A monoclonal antibody of the class IgG or IgM, derived from the fusion of a murine myeloma cell and a murine antibody-producing lymphoid cell, demonstrating specific reactivity to a phosphotyrosine moiety on phosphotyrosine-containing proteins. (
  • 2. The monoclonal antibody of claim 1 wherein the antibody demonstrates positive detection of antigenic determinants of phosphotyrosine-containing proteins by immunosorbent and electrophoretic assays. (
  • 5. The antibody of claim 1 wherein the antibody demonstrates positive reactivity with phosphotyrosine-containing proteins from animal cells. (
  • 7. A murine hybridoma cell line characterized by its production of monoclonal antibodies of the class IgG or IgM demonstrating specific reactivity to a a phosphotyrosine moiety on phosphotyrosine-containing proteins. (
  • 8. The cell line of claim 7 wherein the antibodies demonstrate positive detection of antigenic determinants of phosphotyrosine containing proteins by immunosorbent and electrophoretic assays. (
  • 11. The cell line of claim 7 wherein the antibodies demonstrate positive reactivity with phosphotyrosine-containing proteins from animal cells. (
  • The antibodies are not transgenic mouse model (a human immune system which has been 'grafted' within a mouse model) having been 'vaccinated' with specific and selected purified proteins. (
  • Morrison SL, Johnson MJ, Herzenberg LA, Oi VT (1984) Chimeric human antibody molecules: mouse antigen-binding domains with human constant region domains. (
  • Whole antibody and fragments retaining the antigen‐binding site. (
  • The hallmark of a therapeutic monoclonal antibody is to bind to its target antigen (e.g., a cancer cell) with high affinity and specificity and render its destruction. (
  • In ovarian cancer, a monoclonal antibody is being developed against an antigen called KAAG-1, that is over-expressed in greater than 90% of ovarian tumors. (
  • Most patients with C. neoformans infections have a high concentration of serum polysaccharide antigen and low titers of serum antibodies to the capsular polysaccharide ( 11 ). (
  • However, IgG2 is also utilized for the development of therapeutic when neutralization of soluble antigen with reduce effector function is required, with some drugs in late stage development and also approved for commercial use. (
  • The stability of this biomolecule is attributed to it physical property such as inter and intraspecific disulphide bond, and diversity of antigen recognition by antibody makes this molecule target for therapeutic development [ 1 ]. (
  • This protective substance was now known as an immunoglobulin which are glycoproteins called antibodies produced by plasma cells, they mediate immunity by specific binding to an antigen. (
  • The efficiency of cell destruction by complement lysis or opsonization depends on a number of factors such as antibody specificity and isotype as well as certain properties of the target antigen. (
  • In some instances cells can escape destruction by redistributing and eventually losing the antigen-antibody complexes from their surface. (
  • Of course, an antibody is a blood protein produced to counteract a specific antigen, or foreign substance such as bacteria, viruses or another foreign substance detected by the body. (
  • This occurs by inserting the antigen-specific variable domain of a mouse antibody on the constant domains of a human antibody, producing antibodies that are up to 65% humanized [ 5 , 6 ]. (
  • The antibodies, which have demonstrated affinity for a variety of molecules containing o-phosphotyrosine residues, were prepared using a synthetic analog, p-azobenzyl phosphonate (ABP) covalently linked to a carrier protein, as the antigen. (
  • In various embodiments, the present invention is drawn to antibodies or antigen-binding fragments thereof that bind to a vertebrate high mobility group box (HMGB) polypeptide, methods of detecting and/or identifying an agent that binds to an HMGB polypeptide, methods of treating a condition in a subject. (
  • 1. An antibody produced by a murine hybridoma deposited as ATCC Accession Number PTA-5433, or an antigen-binding fragment thereof. (
  • 4. The isolated cell of claim 3 , wherein said isolated cell is selected from the group consisting of an immortalized B cell, a hybridoma and a recombinant cell comprising one or more exogenous nucleic acid molecules that encode said antibody or antigen-binding fragment of said antibody. (
  • 5. An antibody or antigen-binding fragment thereof wherein said antibody or fragment comprises the light chain CDRs (CDR1, CDR2 and CDR3) and the heavy chain CDRs (CDR1, CDR2 and CDR3) of the 6E6 HMGB1 monoclonal antibody (mAb) produced by the murine hybridoma deposited as ATCC Accession Number PTA-5433. (
  • 6. The antibody or antigen-binding fragment of claim 5 wherein said antibody or antigen-binding fragment further comprises a human framework region. (
  • b) one or more ancillary reagents suitable for detecting the presence of a complex between said antibody or antigen-binding fragment and said HMGB1 polypeptide or said portion thereof. (
  • Köhler G, Milstein C (1975) Continuous cultures of fused cells secreting antibody of predefined specificity. (
  • Their therapeutic specificity makes them ideally suited for helping to minimize adverse side effects, especially when highly toxic drug substances must be delivered. (
  • The antibodies are not 'humanized' rat and mouse monoclonal antibodies where the original antibody affinity and specificity are not maintained, and the chances of immunogenicity are increased. (
  • The Fab fragments contain the variable domains, which consist of three antibody hypervariable amino acid domains responsible for the antibody specificity embedded into constant regions. (
  • Characterization of therapeutic antibodies and related products. (
  • State-of-the-Art and Emerging Technologies for Therapeutic Monoclonal Antibody Characterization Volume 3. (
  • In a previous study, we showed that antigens secreted by S. schenckii induced a specific humoral response in infected animals, primarily against a 70-kDa molecule, indicating a possible role of specific antibodies against this molecule in infection control. (
  • One therapeutic use for monoclonal antibody technology is the elimination of categories of unwanted cells by virtue of their distinct cell surface antigens. (
  • Starting from the observation that rabbit antisera can be made more effective at killing tumour cells if they are first rendered univalent by limited proteolysis, we have now prepared a number of monovalent rat monoclonal antibodies to human cell-surface antigens. (
  • We find that these antibodies are no longer able to bring about modulation of their target antigens and have an enhanced facility for lysis with human complement. (
  • The road to individualized therapy goes through detecting specific targets (e.g., antigens), suitable for influence, and their selective targeting by using specially designed molecules (e.g., antibodies). (
  • In addition to targeting cancer antigens antibodies can also modulate immunological pathways that are critical to immune surveillance. (
  • This invention relates to the production of and applications for monoclonal antibodies specific for prostatic tumor antigens. (
  • The four known IgG subclasses are involved in antibody-dependent cellular cytotoxicity.Antibodies are a key component of the adaptive immune response, playing a central role in both in the recognition of foreign antigens and the stimulation of an immune response to them. (
  • The advent of monoclonal antibody technology has made it possible to raise antibodies against specific antigens presented on the surfaces of tumors. (
  • Additionally, adverse reactions from these antibodies may occur because of long-lasting response to antigens. (
  • Monoclonal antibodies are protein molecules made in the laboratory from hybridoma cells (stable cell lines derived by fusing antibody‐producing cells from immunised animals with cells that confer immortality and high‐yield antibody production) or by recombinant deoxyribonucleic acid (DNA) technology. (
  • Neutralization of West Nile virus (WNV) in vivo correlates with the development of an antibody response against the viral envelope (E) protein. (
  • Using random mutagenesis and yeast surface display, we defined individual contact residues of 14 newly generated monoclonal antibodies against domain III of the WNV E protein. (
  • A therapeutic monoclonal antibody, infliximab, was used as a model protein to evaluate the functionality. (
  • 1-4 For the analysis of charged species of antibodies, ion exchange chromatography (IEX) has a widespread use in the biopharmaceutical industry for its ability to resolve species related to protein conformation, size, sequence variants, glycosylation, and post-translational modifications. (
  • The formation of ADA can have impact on safety, efficacy, and PK of a therapeutic protein. (
  • ADA-driven effects on safety include hypersensitivity reactions ( 1 , 2 ), whereas the efficacy of the therapeutic protein can be affected in two different ways: either by reducing or eliminating its biological activity or by changing its PK properties and thus altering exposure. (
  • The former effect is caused by ADA binding to the epitopes on the therapeutic protein that are essential for biological activity (so-called neutralizing antibodies), while all ADA, both neutralizing and non-neutralizing, may change clearance of the therapeutic protein. (
  • Such change in clearance alters the exposure to the therapeutic protein and thus its efficacy. (
  • Monoclonal antibodies that specifically target SIGLEC-15, a cell surface protein that is stimulated during early osteoclast differentiation, cause an inhibition of this process. (
  • Robust techniques combining an antibody library displayed on the phage surface and protein microarray allowed the identification of auto antibodies recognized by patient sera. (
  • Population pharmacokinetics of sibrotuzumab, a humanized monoclonal antibody directed against fibroblast activation protein, were determined after multiple intravenous infusions of dosages ranging from 5 mg/m(2) to an absolute dose of 100 mg, in patients with advanced or metastatic carcinoma. (
  • A method of preparing high purity procoagulant protein comprising the steps of (a) adsorbing a VIII:C/VIII:RP complex from a plasma or commercial concentrate source of factor VIII onto agarose beads bound to a monoclonal antibody specific to VIII:RP, (b) eluting VIII:C with a salt solution, (c) adsorbing. (
  • 15. In a method for purifying Factor VIII procoagulant activity protein from plasma or concentrate, the improvement comprising the step of passing said plasma or concentrate through a chromatographic type column having adsorbent to which is bound monoclonal antibodies which is specific to VIII:RP and eluting the VIII-C therefrom. (
  • The traditional method involves treating hepatocyte cocultures with the therapeutic protein, which detects hepatocyte- and macrophage-mediated suppression of cytochrome P450 (P450). (
  • The new method involves treating whole human blood with a therapeutic protein to stimulate the release of cytokines from peripheral blood mononuclear cells (PBMCs), after which plasma is prepared and added to the hepatocyte coculture to evaluate P450 enzyme expression. (
  • Some regulatory agencies use the terms biological medicinal products or therapeutic biological product to refer specifically to engineered macromolecular products like protein- and nucleic acid -based drugs , distinguishing them from products like blood, blood components, or vaccines, which are usually extracted directly from a biological source. (
  • One monoclonal antibody, E16, neutralized 10 different strains in vitro, and showed therapeutic efficacy in mice, even when administered as a single dose 5 d after infection. (
  • During research and early development of new therapeutic biologics, animal studies are required to assess their efficacy, pharmacokinetic (PK) and pharmacodynamic (PD) properties, and safety. (
  • Blockade of B7-H1 or PD-1 by specific monoclonal antibodies could reverse this resistance and profoundly enhance therapeutic efficacy. (
  • To test whether one of these cocktails (MB-003) demonstrates efficacy as a therapeutic (after the onset of symptoms), we challenged NHPs with EBOV and initiated treatment upon confirmation of infection according to a diagnostic protocol for U.S. Food and Drug Administration Emergency Use Authorization and observation of a documented fever. (
  • As more patients undergo MAb therapy, there is a perceived need for monitoring of MAb therapeutic efficacy and understanding loss of response when patients fail treatment. (
  • Antibodies to the capsular polysaccharide are opsonic ( 31 , 39 , 41 , 48 , 56 ) and can enhance the therapeutic efficacy of amphotericin B ( 12 , 21 , 38 ), fluconazole ( 34 ), and flucytosine ( 15 ). (
  • In the past, antibody administration was used for therapy of human cryptococcal infection, but too few patients were treated to draw conclusions regarding the efficacy of antibody therapy (for a review see reference 20 ). (
  • Cancer therapies based on monoclonal antibodies are widely successful, yet have limited efficacy against CNS metastases, owing to the low levels of the drug reaching the tumour site. (
  • As a large variety of mAb-based agents targeting a plethora of cytokines, chemokines, adhesion and co-stimulatory molecules, receptors, as well as diverse cell types, are presently under investigation, the therapeutic armamentarium of the clinician is expected to greatly broaden in the near future, providing improved patient care for a wide range of devastating diseases of our times. (
  • I'm going to be using his probes antibodies that target molecules of the immune system, and I'm going to show you that we can with antibodies in rodents, give short-term treatments to get long-term benefits that stop unwanted immune responses using transplantation as my model system but such principles could easily apply to autoimmune diseases and other forms of chronic immune pathology. (
  • Cell line development and assurance of monoclonality are critical steps in the process of generating biopharmaceutical molecules, such as monoclonal antibodies . (
  • More recently antibodies have been used to bind to molecules involved in T-cell regulation to remove inhibitory pathways that block T-cell responses. (
  • Immunoglobulin G (IgG) antibodies are large heterodimeric molecules, approximately 150 kDa and are composed of two kinds of polypeptide chain, called the heavy (~50kDa) and the light chain (~25kDa). (
  • This preclinical study suggests that anti-EpCAM antibody conjugates with α-amanitin have the potential to be highly effective therapeutic agents for pancreatic carcinomas and various EpCAM-expressing malignancies. (
  • The method accurately quantified PS80 in 18 different sample formulations including monoclonal antibodies, bispecific antibodies, antibody drug conjugates (ADCs), and bispecific ADCs, thereby establishing a truly selective method free of matrix interference. (
  • Anti-EpCAM antibodies have shown promise in preclinical studies, but showed no tumor regression in a recent phase II clinical trial. (
  • We recently described the development of a novel humanized monoclonal antibody that targets uPAR and has anti-tumor activity in multiple xenograft animal tumor models. (
  • The development of evasion mechanisms within tumor microenvironment may be responsible for poor therapeutic responses. (
  • The Company's most advanced monoclonal antibody targets a secreted factor called clusterin, which plays an important role in tumor progression and invasion. (
  • Studies in cancer xenografts have revealed that this antibody significantly reduces the dispersion of ovarian tumor cells, a process that remains a major clinical challenge with current standard of care. (
  • In an orthotopic PDX model, animals receiving chemoimmunotherapy with an anti-GD2 antibody, GM-CSF, and a soluble IL15/IL15Rα complex had greater tumor regression than did those receiving chemotherapy alone ( P = 0.012) or combined with anti-GD2 antibody and GM-CSF with ( P = 0.016) or without IL2 ( P = 0.035). (
  • The therapeutic removal of this tumor-tolerance of course bears the risk of inducing auto-immunity [ 3 ]. (
  • Monoclonal antibodies can be further segmented into fully human antibody (with an immune system target), chimeric monoclonal antibody (with a tumor target) and humanized monoclonal antibody (with a circulatory system target). (
  • Indirect Immunoperoxidase Staining of Tumor Specimens of Monoclonal Antibodies 7E11C5. (
  • The monoclonal antibodies exhibit a high level of binding to human prostatic cancer cells and normal prostatic epithelium and are potentially capable of experimental in vivo tumor localization. (
  • Monoclonal antibodies can target tumor cells or abnormal cells in the body that are recognized as body cells, but are debilitating to one's health. (
  • After a single intravenous injection of the same mAb as used for tolerance induction, the pharmacokinetics of the mAb and formation of anti-drug antibodies (ADA) in plasma were assessed using ELISA. (
  • The immune response usually leads to the formation of drug-specific anti-drug antibodies (ADA)-the measurable hallmark of immunogenicity. (
  • Current major therapeutic applications of monoclonal antibodies include cancer, chronic inflammatory disease, and infection and they constitute the largest and fastest growing sector of the biological pharmaceutical industry. (
  • In postexposure therapeutic trials in mice, a single dose of humanized E16 protected mice against WNV-induced mortality, and may therefore be a viable treatment option against WNV infection in humans. (
  • One day after infection, the animals that received the antibodies showed an immediate drop in the amount of virus, and after three days, they had a more than 500-fold reduction in virus compared to the control group, the researchers reported. (
  • The researchers also assessed the effectiveness of giving the antibody as a treatment following infection, but it was not effective when administered after exposure to the virus. (
  • These results indicate the m336 antibody administered prior to exposure is able to prevent MERS-CoV infection and warrants further development as a medical countermeasure against MERS-CoV infection," the researchers reported. (
  • Therapeutic Monoclonal Antibodies for Ebola Virus Infection Derived from Vaccinated Humans. (
  • A cross-reactive cocktail of four antibodies, targeting the latter three non-overlapping epitopes, given on day 3 of EBOV infection, completely protected guinea pigs. (
  • Ironically, even after a decade of research on coronavirus, still there are no licensed vaccines or therapeutic agents to treat coronavirus infection which highlights an urgent need to develop effective vaccines or post-exposure prophylaxis to prevent future epidemics. (
  • Hence, the research advancements on SARS-CoV treatment might help scientific community in quick understanding of this virus pathogenesis and develop effective therapeutic/prophylactic agents to treat and prevent this infection. (
  • Here, we show that ZIKV-195, a potently neutralizing human monoclonal antibody, has postexposure therapeutic activity against ZIKV infection in a mouse model. (
  • c) humanised antibody (murine complementarity‐determining regions on a human framework) and (d) completely human antibody. (
  • We now report the results of our studies where we have shown comparable fibril binding and effective, although somewhat reduced, amyloidolytic activity of the modified antibody as compared with its murine (native) counterpart. (
  • The murine monoclonal antibody (MAb) 18B7 [immunoglobulin G1(κ)] is in preclinical development for treatment of Cryptococcus neoformans infections. (
  • Antibody humanization bypasses this bottleneck, minimizing the HAMA response by replacing murine sequences with human framework homologous sequences [ 6 ]. (
  • 3. An isolated cell that produces the 6E6 HMGB1 monoclonal antibody (mAb) produced by the murine hybridoma deposited as ATCC Accession Number PTA-5433. (
  • Human Anti-Murine Antibody (HAMA) negative within 21 days prior to study enrollment. (
  • Four major antibody types that have been developed are murine, chimeric, humanised and human. (
  • Initial therapeutic antibodies were murine analogues (suffix -omab). (
  • Initially, murine antibodies were obtained by hybridoma technology, for which Jerne, Köhler and Milstein received a Nobel prize. (
  • However the dissimilarity between murine and human immune systems led to the clinical failure of these antibodies, except in some specific circumstances. (
  • Monoclonal antibodies can mediate antibody‐mediated cytotoxicity by linking the target cells to cytotoxic cells through their binding sites and Fc sites. (
  • 692/29 was able to kill tumour cells over-expressing Lewisy/b directly, as well as by antibody and complement mediated cytotoxicity (ADCC/CDC), but failed to kill cells expressing low levels of these haptens. (
  • We compared the immunoadjuvant effects of IL15 with those of IL2 for enhancing antibody-dependent cell-mediated cytotoxicity (ADCC) in neuroblastoma. (
  • The antitumor effects of this therapy are executed by natural killer (NK) cells via antibody-dependent cell-mediated cytotoxicity (ADCC). (
  • The chromatogram shows a gradient spanning from pH 5.20 to 7.90 is formed for the separation of lysine truncation charge variants of a chimeric monoclonal antibody (infliximab). (
  • Monoclonal antibody (MAb) therapy is a relatively novel, growing field in the pharmaceutical industry, with an expected $100 billion dollars in sales across the world in 2017. (
  • Athens, Georgia, April 19, 2017 - Abeome Corporation announced today that it has signed a Research Collaboration Agreement (RCA) with Centers for Disease Control and Prevention (CDC) for the identification of novel antibodies binding to the Zika virus using Abeome's proprietary AbeoMouseTM platform. (
  • The development of a successful therapeutic mAb requires the identification and creation of a selective and potent molecule that performs the needed task, humanization of sequences, affinity maturation, Fc engineering to modulate effector functions, and engineering to address biophysical liabilities that would negatively impact manufacturability and/or patient effectiveness. (
  • Antibody-mediated effector functions, including phagocytosis and NK cell activation, were associated with protection, particularly for antibodies with moderate neutralizing activity. (
  • These antibodies have: a short half-life in vivo (due to immune complex formation), limited penetration into tumour sites and inadequately recruit host effector functions. (
  • McCafferty J, Griffiths AD, Winter G, Chiswell DJ (1990) Phage antibodies: filamentous phage displaying antibody variable domains. (
  • Monoclonal antibodies can be derived from B‐cells from immunised animals, humans with autoimmune diseases and de novo by phage display. (
  • Since the advent of phage display technology, dating back to 1985, antibody libraries displayed on filamentous phage surfaces have been used to identify specific binders for many different purposes, including the recognition of tumors. (
  • Phage display represents a high-throughput technique for screening billions of random fusion antibodies against virtually any target on the surface or inside cancer cells, or even soluble markers found in patient serum. (
  • By using a human combinatorial antibody library and a phage display approach, a cohort of fully human antibodies against SEB were identified. (
  • AIDS Clinical Trials Group (1997) MSL‐109 adjuvant therapy for cytomegalovirus retinitis in patients with acquired immunodeficiency syndrome: the monoclonal antibody cytomegalovirus retinitis trial. (
  • 70-chapter authoritative reference that covers therapeutic monoclonal antibody discovery, development, and clinical applications while incorporating principles, experimental data, and methodologies. (
  • During the last two decades, the rapid growth of biotechnology-derived techniques has led to a myriad of therapeutic recombinant monoclonal antibodies with significant clinical benefits. (
  • A brief overview of recombinant therapeutic monoclonal antibodies including their structures, productions, and clinical applications is presented. (
  • To develop this reagent for clinical use, the 11-1F4 mAb was chimerized and its activity compared with that of the unmodified antibody. (
  • Current Constructs and Targets in Clinical Development for Antibody-Based Cancer Therapy. (
  • Almost ever since their invention, monoclonal antibodies have held the promise of cancer-specific drug targeting - Paul Ehrlich's "magic bullet" -- but only during the past decade have a modest number of anti-cancer antibodies received approval for clinical use. (
  • Monoclonal antibodies are currently in clinical development or undergoing clinical trials to treat COVID-19. (
  • MAb 2H1 (immunoglobulin G1 [IgG1]) is a protective antibody that has been extensively characterized, and it was our leading candidate for clinical development until we encountered problems of aggregation during purification. (
  • In this review we focus on the spectrum of irAEs associated with immune checkpoint antibodies, discussing the pharmacological treatment strategy and possible clinical impact. (
  • Examples of such antibodies will be discussed here with emphasis on those used as probes for molecular imaging and other clinical trials. (
  • The envisioned clinical applications of the developed antibody will be both prophylactic to provide passive immunity to individuals at high risk via an imminent bioterror attack, and as a therapeutic antidote for treatment of individuals already exposed to SEB. (
  • The monoclonal antibodies of this invention possess distinctive characteristics and capabilities which make them suitable for in vitro clinical diagnostic and prognostic purposes. (
  • Monoclonal antibodies have multiple utilities in therapy as they can recognise specific structures in targets such as bacteria, viruses, cancer cells, etc. (
  • Some of the most successful targets of monoclonal antibodies are constituted by the epidermal growth factor receptor family spearheaded by the epidermal growth factor receptor (EGFR). (
  • Alethia is a Montreal-based biotechnology company that was created in 2002 aimed at discovering tissue-specific disease targets and developing monoclonal antibodies for use as focused therapeutic in areas of unmet medical needs. (
  • This analysis also confirmed that the site against which the Company's already produced anti-HIV monoclonal antibodies (called Clone 3) targets one conserved site on the HIV virus, which site is 98% conserved (either directly or by way of conservative amino acid substitutions) overall 87,336 HIV isolates curated (analyzed) by the Company using Artificial Intelligence. (
  • Human antibodies are of particular interest due to a lower immunogenicity response [ 1 ]. (
  • Trastuzumab (herceptin) is a humanized IgG1 kappa monoclonal antibody (mAb). (
  • This Editorial aims to present the background to the recent authorization of tocilizumab, a humanized therapeutic monoclonal antibody to the IL-6 receptor (IL-6R), for hospitalized patients with moderate and severe COVID-19 and future combination therapies. (
  • In most of these disciplines, biologics have added major therapeutic options for the treatment of many diseases, including some for which no effective therapies were available, and others where previously existing therapies were clearly inadequate. (
  • It analyses five major therapeutic areas where these antibodies find its applications. (
  • Lonberg N, Huszar D (1995) Human antibodies from transgenic mice. (
  • Expression of an anti-botulinum toxin A neutralizing single-chain Fv recombinant antibody in transgenic tobacco. (
  • The optimized hMabs will be tested within Aim 4 via a humanized transgenic mouse model and rhesus aerosol challenge model for toxic shock to identify the final preclinical therapeutic candidate against SEB intoxication. (
  • These novel drugs can be used either as a monotherapy or in combination with other conventional therapeutic modalities, particularly if the disease under treatment is refractory to therapy using solely conventional techniques. (
  • See the list of FDA-approved therapeutic monoclonal antibodies in the monoclonal antibody therapy page. (
  • Carbonic Anhydrase IX as an Anticancer Therapy Target: Preclinical Evaluation of Internalizing Monoclonal Antibody Directed to Catalytic Domain. (
  • These observations, together with an association between rapid clearance of capsular polysaccharide after antibody administration in humans ( 20 ), mice ( 38 ), and rats ( 19 ), suggest antibody therapy may have a role in the therapy of human cryptococcosis. (
  • This paper explores some of the exciting directions mAb therapy is heading, and the challenges and enabling technologies impacting this therapeutic area. (
  • Antibody therapy directed against several negative immunologic regulators (checkpoints) is demonstrating significant success in the past few years. (
  • The advantage of active monoclonal antibody therapy is the fact that the immune system will produce antibodies long-term, with only a short-term drug administration to induce this response. (
  • Passive monoclonal antibody therapy can ensure consistent antibody concentration, and can control for adverse reactions by stopping administration. (
  • Monoclonal antibody therapy may prove to be beneficial for cancer, autoimmune diseases, and neurological disorders that result in the degeneration of body cells, such as Alzheimer's disease. (
  • Monoclonal antibody therapy can aid the immune system because the innate immune system responds to the environmental factors it encounters by discriminating against foreign cells from cells of the body. (
  • We report here that constitutive or inducible expression of B7-H1, a B7 family molecule widely expressed by cancers, confers resistance to therapeutic anti-CD137 antibody in mice with established tumors. (
  • Monoclonal antibody-based treatment of cancer has been established as one of the most successful therapeutic strategies for both hematologic malignancies and solid tumors. (
  • Andreakos E, Taylor PC, Feldmann M (2002) Monoclonal antibodies in immune and inflammatory diseases. (
  • The purpose of this study is to test the feasibility of neonatal immune tolerance induction in mice to enable long-term pharmacokinetic studies with immunogenic therapeutic monoclonal antibodies (mAb). (
  • Overall, the present study demonstrated the suitability of neonatal immune tolerance induction for a 4-week single dose study in adult mice with a human therapeutic mAb that is otherwise immunogenic in laboratory animals. (
  • The human immune response to dengue virus is dominated by highly cross-reactive antibodies endowed with neutralizing and enhancing activity. (
  • Monoclonal antibodies are monospecific antibodies which are made from identical immune cells that are all clones of a unique parent cell. (
  • Antibodies are nanosize biological products that are part of the specific immune system. (
  • However, antibodies mediate an array of antiviral functions including neutralization as well as engagement of Fc-domain receptors on immune cells, resulting in phagocytosis or NK cell-mediated killing of infected cells. (
  • Antibodies are produced from human 'immune-B cells,' obtained from convalescent individuals who have recovered from the target virus. (
  • Monoclonal antibodies can be acquired in the immune system via passive immunity or active immunity. (
  • Recent studies have demonstrated that cocktails of monoclonal antibodies are effective at preventing morbidity and mortality in nonhuman primates (NHPs) when administered as a post-exposure prophylactic within 1 or 2 days of challenge. (
  • Potently neutralizing antibodies are of interest due to their prophylactic and therapeutic potential. (
  • Approximately 15-40% of all cancers develop metastases in the central nervous system (CNS), yet few therapeutic options exist to treat them. (
  • Encapsulation and molecular targeting of therapeutic antibodies could become an option for the treatment of cancers with CNS metastases. (
  • In addition, the antibodies have potential uses in diagnosis of a variety of diseases, including certain cancers. (
  • Research and development is underway to create antibodies for diseases (such as rheumatoid arthritis, multiple sclerosis, Alzheimer's disease, Ebola and different types of cancers). (
  • The results show that both the variable and constant regions of MAb 18B7 are biologically functional and support the use of this MAb in human therapeutic trials. (
  • This proposal is aimed at preclinical development of fully human therapeutic anti-SEB monoclonal antibodies (hMabs). (
  • Ferrara N, Hillan KJ, Gerber HP and Novotny W (2004) Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. (
  • Along with our current shareholders, AgeChem's support provides us with the necessary financial resources to continue building Alethia's therapeutic product pipeline, validating the potential of our target discovery platform and maximizing the value of our programs for partnership opportunities," said Yves Cornellier, President and Chief Executive Officer of Alethia. (
  • We are very excited about working with the management of the company and our investment partners to build a leading target discovery and therapeutic mAb organization in Canada. (
  • Abeome is a privately-held antibody discovery company focused on the high-throughput selection, analysis and synthesis of monoclonal antibodies with a primary objective to develop best-in-class prescription products for the therapeutic antibody market - the fastest growing segment of global drug sales. (
  • Development of a humanized monoclonal antibody with therapeutic potential against West Nile virus. (
  • We continue to be supportive and enthusiastic about Alethia's potential to address unmet medical needs in a variety of indications including cancer, as the company's development activities begin to yield very promising therapeutic candidates," said Ela Borenstein, Director at BDC and representing GO Capital. (
  • A monoclonal antibody has proven effective in preventing Middle Eastern Respiratory Syndrome (MERS) in lab animals, suggesting further development as a potential intervention for the deadly disease in humans, according to new research. (
  • Monoclonal antibody drug development is a tedious and long-term process requiring putting many factors into consideration. (
  • This review examines the suitable IgG subclasses with the capability of ADCC, CDC, and C1q mediation, and also provides future recommendation on the suitability of less stable IgG subclasses in the therapeutic development. (
  • A significant advance in this area is the development of therapeutic monoclonal antibodies. (
  • This proposal brings together expertise from Integrated Biotherapeutics Inc, the US Army Medical Research Institute of Infectious Diseases (USAMRIID), Biocon, Inc., as well as MorphoSys AG and its subsidiary AbD-Serotec, in anti-toxin therapeutic development, animal studies with biothreat agents, and a novel proprietary technology for development of fully human antibodies. (
  • Identifying CQAs for a biotech therapeutic is the first and arguably the most difficult step in implementation of quality by design (QbD) for development and production of biopharmaceuticals (3, 4). (
  • These are exciting times to be involved in monoclonal antibody (mAb) and biopharmaceutical analysis. (
  • In this 30th article of the "Elements of Biopharmaceutical Production" series, the authors focus on proposing an approach towards establishing CQAs for a mAb therapeutic product. (
  • In Aim 3, the lead therapeutic antibodies will be subjected to affinity maturation, if necessary, by using a proprietary mutagenesis technology that will result in a second generation of optimized anti-SEB hMabs. (
  • Monoclonal antibodies can be produced in large amounts in homogeneous and reproducible form for diagnostic and therapeutic purposes. (
  • Monoclonal antibodies are currently used for many diagnostic and therapeutic applications. (
  • This process, known as antigenic modulation, generally depends on bivalent antibody binding. (
  • Therapeutic potential of monovalent monoclonal antibodies. (
  • This is a list of therapeutic, diagnostic and preventive monoclonal antibodies, antibodies that are clones of a single parent cell. (
  • amanitin have the potential to be highly effective therapeutic agents for pancreatic carcinomas and various EpCAM-expressing malignancies. (
  • Chemical cross-linking was conducted to covalently conjugate α-amanitin, a toxin known to inhibit DNA transcription, with chiHEA125, a chimerized anti-EpCAM monoclonal antibody, to generate the antibody-drug conjugate α-amanitin-glutarate-chiHEA125 (chiHEA125-Ama). (
  • We measured the concentration of human IgG antibodies in serum samples from necropsied hamsters using the IgG human SimpleStep ELISA Kit (Abcam, according to the manufacturer´s instructions. (
  • Serum samples from necropsied animals on day 10 postinfection were used to measure the concentration of human IgG antibodies by ELISA. (
  • A therapeutic monoclonal antibody and its Fab and Fc fragments were recently investigated using differential scanning fluorimetry, temperature-ramped dynamic light scattering, and turbidity measurements. (
  • We report here a 4-Å-resolution cryo-electron microscopy structure of the ZIKV virion in complex with Fab fragments of the potently neutralizing human monoclonal antibody ZIKV-195. (
  • Therapeutic recombinant monoclonal antibodies represent the state-of-the-art of biomedical research and provide effective strategies to treat a number of diseases for which there are no available treatments. (
  • To address the need, a research team from the National Institute of Allergy and Infectious Diseases (NIAID) and NCI characterized a human monoclonal antibody, m336, which has the ability to attach itself to the MERS virus in a way that renders the virus harmless. (
  • The group conducted a series of experiments to see if the antibody would protect laboratory animals from the disease, and the results were recently published in The Journal of Infectious Diseases . (
  • examples of such monoclonal antibodies for use in various diseases are given in the table below. (